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Abstract 
In the mass screening of Traditional Chinese Medicine against thalassemia 
and leukemia in our lab, the partially purified extract (LC976) of a Trichosanthes sp. 
{Trichosanthes kirilowii Maxim) was identified having probable effect against the 
diseases. We then carried out further studies on this extract, and my project focused on 
its anti-cancer effect. 
First, the action spectrum of LC976 was tested. It was to evaluate the 
anti-proliferative effect of LC976 on various human cell lines. MTT assay results 
showed that LC976 was capable of inhibiting proliferation and being cytotoxic to all the 
9 human cell lines evaluated, whereas BrdU cell proliferation ELISA further confirmed 
the anti-proliferative effect of LC976. 
Next, we focused on K-562 and studied the action pathway of LC976, 
whether it induced apoptosis or necrosis in the cells. Apoptotic features of the LC976 
treated cells were observed by propidium iodide staining and FACS analysis of cells 
stained with Annexin V-FITC and propidium iodide. Caspase 8，9，2 and probably 
caspase 3 in K-562 cells were found activated. This indicates that both the 
death-receptor mediated pathway and the mitochondria mediated pathway were 
activated by LC976 for apoptosis. 
More，we studied the action selectivity of LC976, whether its action was 
differential between human cancer cells and normal lymphocytes. MTT assay showed 
that normal lymphocytes were killed by LC976，and heavy apoptosis was shown by 
Annexin V-FITC FACS. 
Therefore LC976 was toxic to both the cancer cells and normal lymphocytes. 
However the actual toxicity of the drug could be evaluated with further in vivo assays 
using mouse models. 
And an interesting observation was made when LC976 induced the 
differentiation of K-562 cells to develop some dendrite-like cytoplasmic extensions. But 
i 
this still requires further study to evaluate whether LC976 can induce dendritic cell 
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Chapter 1 Introduction 
Chapter 1 Introduction 
1.1 Trichosanthes spp. 
Trichosanthes spp. (f舌樓）have a long history to be used in Chinese 
medicine. Trichosanthes belongs to the family Cucurbitaceae, and Trichosanthes itself 
contains many species, which are generally different closely related gourds (Table 1.1). 
In China, the most commonly used Trichosanthes include Trichosanthes 
kirilowii Maxim (瓜簍)and Trichosanthes rosthornii Harms (雙邊丰舌樓).Their roots 
are dried and made to powder and are called Tienhuafen (天花粉).To a more minor 
proportions, Trichosanthes rosthornii Harms van multicirrata (多卷須丰舌樓)， 
Trichosanthes laceribractea Hayata (長萼t舌樓)，Melothria heterophylla (Lour.) Cogn. 
(異葉'馬 i j ^ ) and Trichosanthes cucumeroides (Ser.) Maxim (王瓜）are also used to 
make Tienhuafen. Their functions are not much different. 
However, Trichosanthes hupehensis C. Y. Cheng et Yueh (湖北栝樓）and 
Trichosanthes cavaleriei Levi (長貓瓜)cause adverse effect like nausea and vomiting 
when intake. 
In my project, Trichosanthes kirilowii Maxim was used. It is one of the most 
popularly used Trichosanthes spp. 
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1.1.1 Use of Trichosanthes 
Shen Nong Ben Cao Jing (神農本草經）describes the root of Trichosanthes 
to be bitter, cold and non-toxic. And the herb was used to treat thirst, body heat, anxiety, 
general fever, yellowish body and face (jaundice), drying mouth and lips, shortness of 
breath, suppression of menstruation (amenorrhoea) and frequent urination. 
In more recent studies, not only the root of Trichosanthes is useful, its fruit 
and seed are also found to have valuable biological activities. It has been found that 
compounds extracted from the plant have abortion inducing, anti-cancer and even 
anti-HIV effect. 
Since we are still unsure about the identity and nature of the compound that 
is responsible for the anti-cancer activity demonstrated in the project, here we review 
the various currently investigated compounds in Trichosanthes. 
1.1.2 Trichosanthin 
Trichosanthin is one of the most extensively studied proteins extracted from 
the root of Trichosanthes kirilowii Maxim. It is used as an abortifacient drug to induce 
early and mid-gestation abortion, which aids the implementation of one-child policy in 
Mainland China. It is also used to cure ectopic pregnancy. Later it was found to have 
anti-cancer and anti-HIV activities. 
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Abortifacient activity 
In early studies, it was reported that Trichosanthin directly act on the 
placental trophoblasts with certain specificity. It caused necrotic denaturation of the 
syncytiotrophoblasts of the placental villi so that the disintegrated cells clogged the 
blood circulation (Authors not listed, 1976). Later studies in mice showed that 
Trichosanthin caused a marked decrease in fetal viability and an increase of 
abnormalities (Chan et al.，1993a), which its toxicity would not affect later pregnancies 
when Trichosanthin was not administered (Chan et al , 1993b). 
It has been shown that Trichosanthin is a ribosome inactivating protein, 
which its abortifacient activity is due to its RNA N-glycosidase activity. RNA 
N-glycosidase is an enzyme to cleave the glycosidic bond between the ribose and the 
nucleotide at specific sites (Peumans et al., 2001). The ribosomes become functionless 
and protein synthesis stops upon ribosome inactivation. It was reported that 450 
nucleotides fragment was cleaved off and released in ribosomal RNAs isolated from 
trichosanthin treated rat liver ribosomes, followed by aniline treatment. And the site of 
action is at 4324 of 28S rRNA (Zhang and Liu, 1992). 
Beta-trichosanthin was later found in the root of Trichosanthes cucumeroides 
which was demonstrated to be twice as potent as Trichosanthin to induce mid-gestation 
abortion in mice (Yeung and Li, 1987). 
Though Trichosanthin is an effective abortifacient, its use has to be carefully 
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regulated, as it is a potent allergen. Currently doctors will perform allergy test on the 
women forearm before administering the drug. Trichosanthin when injected to mice, it 
activated the complement alternative pathway, elevated the peripheral blood leukocyte 
count as well as neutrophil accumulation (Chen and Ma, 1993). It was also reported 
that it can up-regulate various interleukins and cytokines to induce T helper cell and 
IgE responses (Xu et al.，2001). 
Anti-cancer activity 
Trichosanthin was able to suppress the proliferation of various human T cell 
lines and macrophage cell lines (Zheng et al , 1995), and can also selectively kill 
choriocarcinoma cells (Tsao et al , 1986). Another study reported Trichosanthin when 
injected to mouse model, a delay of tumor formation was observed (Takemoto, 1998). 
It was also showed that Trichosanthin induced apoptosis in K-562 leukemia cells 
(Kong et al., 1998). 
Anti-HIV activity 
It was observed that trichosanthin reduced the level of HIV viral proteins and 
RNA in both acutely and chronically HIV infected lymphocytes and mononuclear 
phagocytes in vitro (McGrath et al., 1989). Later on, patients with acquired 
immunonodeficiency syndrome (AIDS) and AIDS-related complex (ARC) was given 
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trichosanthin together with prostaglandin inhibitors. It was reported that half of the 
patients' immunological status was improved, including a significant increase in CD4+ 
T cells. Some of the patients reported improved appetites and energy level. Though 
most of these patients experienced mild arthralgia, hives and malaise (Mayer et al., 
1992). It was once hypothesized that the anti-HIV-l property of trichosanthin was due 
to its ribosome inactivating activity (Wang et al , 2002). However the same group of 
scientists reported the opposite view when they found a trichosanthin mutant that 
lacked the ribosome inactivating activity and did not inhibit HIV-1 replication (Wang 
et al., 2003). In the most current study, they hypothesized that the anti-HIV-1 
replication of trichosanthin was partly due to the apoptosis induction to the HIV-1 
infected cells. They reported that trichosanthin induced apoptosis in HIV-1 infected 
human T cell cell line more effectively than in non-infected cells (Wang et al., 2005a). 
1.1.3 Karasurin 
Karasurin has been isolated from fresh root tubers of Trichosanthes kirilowii 
Maximowicz var, japonicum Kitamura in Japan, and has been under intensive study. It 
was shown that it had a strong abortive effect in pregnant mice, which the sequence of 
this protein has a considerable similarity to trichosanthin (Toyokawa et al., 1991a; 
Toyokawa et al., 1991c). The 2 polymorphs of the protein, karasurin-A and karasurin-B, 
had no significant difference to induce abortion in mid-term gestation of mice and to 
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inhibit growth of human choriocarcinoma cell line BeWo (Toyokawa et al., 1991b). A 
few years later, karasurin-C was identified with properties similar to karasurin- A and 
B. it was shown that all the karasurins were effective ribosome-inactivating proteins, 
that strongly inhibited in vitro protein translation using the rabbit reticulocyte system 
(Kondo et al., 1996). Karasurin-A was found to have immunosuppressive activity in 
vitro, shown by its ability to inhibit lymphocyte proliferation stimulated with 
lipopolysaccharide (LPS), concanavalin A (Con A) and phytohaemaglutalin (PHA) by 
measuring nitrogen oxide production (Terawaki et al., 1997). These properties suggest 
the karasurins apart from having considerable sequence similarity to trichosanthin; 
they have very similar biochemical activities as well. 
1.1.4 Ribosome Inactivating Proteins 
Apart from trichosanthin and karasurin, scientists have found many other 
ribosome inactivating proteins in the Trichosanthes species. Most of these proteins 
exhibit both the ribosome inactivating and abortifacient actions. These include 
trichokirin (Barbieri et al.，1992), alpha and beta kirilowin (Dong et al., 1994; Wong et 
al., 1996)isolated from Trichosanthes kirilowii seeds and trichomaglin isolated from 
Trichosanthes lepiniate (Chen et al., 1999). While some of the proteins were only 
proved of the ribosome inactivating property, for example trichoanguin isolated from 
Trichosanthes anguina (Chow et al., 1999), trichokirin-S 1 purified from Trichosanthes 
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kirilowii seeds(Li et al., 2003; Tai et al., 2000), and another recombinant protein 
trichomislin that was cloned from the genome of Trichosanthes kirilowii. This protein 
was shown to have ribosome inactivating properties as well as anti-tumor 
properties(Yang et al., 2005). 
1.1.5 Immunosuppresion 
Karounidiol isolated from Trichosanthes kirilowii seeds was observed to 
inhibit 12-0-tetradecanoylphorbol-13 -acetate (TPA) induced inflammatory activity 
(Yasukawa et al., 1994). 5 triterpenes extracted from these seed also showed 
anti-inflammatory effect to inhibit TPA induced ear inflammation in mice(Akihisa et 
al., 1994)，and the extract of the seeds was also observed to have anti-inflammatory 
effect in acetic acid-induced vascular permeability study in mice and 
carrageenin-induced edema study in rats(Ozaki et al , 1996). In another study, the 
extract of Trichosanthes kirilowii fruit was shown to protect against experimental 
gastric lesions in rats (Takano et al., 1990). It was also reported that Trichosanthes 
kirilowii semen was able to inhibit inflammatory response, the induction of 
cytokine-induced neutrophil chemoattractant (CINC) by interleukin-8 (Lee et al., 
1995). 
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1.1.6 Anti-cancer activity 
Karounidiol isolated from Trichosanthes kirilowii seeds was reported to 
suppress the promoting effect of TPA on skin tumor formation in mice(Yasukawa et al.’ 
1994) and being cytotoxic or human renal cancer cell lines(Akihisa et a l , 2001). While 
there were other reports to show extracts of Trichosanthes kirilowii root markly 
inhibited human cervix adenocarcinoma cell line HeLa proliferation and induced 
apoptosis in the cells (Dou and Li, 2003). 
1.1.7 Miscellaneous uses 
Trichosanic acid extracted from Trichosanthes japonica was reported to 
suppress platelet aggregation in human platelets (Takenaga et al., 1988), while later it 
was reported these effects were due to the steroidal compounds (He et al., 2003). The 
water extract of Trichosanthes kirilowii roots was found to reduce the plasma glucose 
level in mice, and glycan trichosan A extracted showed hypoglycaemic activity in 
alloxan diabetic rats (Hikino et al., 1989; Kar et al., 2003)，which this effect was also 
shown by the extract of Trichosanthes cucumerina (Kar et al., 2003). While the extract 
of Trichosanthes anguina showed larvicidal effect against the mosquito Culex 
quinquefasciatus (Prabakar and Jebanesan, 2004). Concerning the anti-HIV effect of 
trichosanthes, TAP 29 extracted from Trichosanthes kirilowii, showed comparable 
anti-HIV activity as trichosanthin by its lower toxicity (Lee-Huang et al., 1991). 
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1.2 Cancer 
Cancer is a notorious and disastrous disease. More than 10 million people are 
diagnosed with cancer each year worldwide, killing 6 million people. In Hong Kong, it 
is the number one life-taking disease, 11907 people died of cancer in 2003. 
Common practices to treat cancer include surgery, chemotherapy and 
radiotherapy. Despite the development of these treatments, each of them has its 
limitations, and many of the treatments are destructive to our body. Many of the cancer 
patients in fact die of the treatments rather than the cancer itself. Also, with the 
numerous cases of drug-resistant cancers, which surgery and radiotherapy are 
inappropriate, there is an utmost urgency to develop better therapeutics to battle these 
out-of-control cells. 
This genetic disease occurs when various cancer-related genes are mutated 
and result in the neoplasm of cells. Normal cells in mammals are under tight control in 
the replication. Most cells are at rest and exit the cell cycle and will not replicate again 
without appropriate signals. While cancer cells are those that escape this control 
mechanism, and divide in an uncontrolled manner. The cancer-related genes are 
generally classified as 3 categories: oncogenes, tumor-suppressor gene and stability 
genes. 
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1.2.1 Oncogenes 
Oncogenes are genes encoding product for the promotion of abnormal cell 
proliferation. In normal conditions, these genes are inactive, as the proto-oncogenes.， 
which only upon mutations that they are activated. The mutation could be chromosome 
translocation, gene amplifications to nucleotide mutations. Endogenous oncogenes 
include the kit gene in gastrointestinal stromal tumors (GISTs), which encode a 
proto-oncogenic receptor tyrosine kinase (KIT). When this protein becomes mutated, it 
would be constantly activated even without the KIT ligand. Therefore downstream cell 
division would constantly take place to cause cancer (Went et al.，2004). Another 
example is c-met, which codes for the tyrosine kinase receptor (RTK) for hepatocyte 
growth factor (HGF). It has been found to be up-regulated in many cancers, like 
gliosarcoma (Reis et al., 2000), prostate carcinoma(Kurimoto et al., 1998) and gastric 
cancer (Inoue et al., 2004). The oncogene product is responsible for the invasiveness 
and motility of the cancer cells (Hammond et al., 2004; Hov et al., 2004). Apart from 
the endogenous oncogenes, some viruses also carry proto-oncogenes, and can be 
introduced to the human genome upon their infection and become activated to 
oncogenes by mutation. These includes v-ras that encodes a small GTPase involved in 
signal transduction from a surface receptor to the nucleus (de Rooij and Bos, 1997; 
Singh et al , 2005), v-raf that is a serine/threonine protein kinase (Rapp et a l , 1983; 
Shimizu et al., 1985), v-src encodes a membrane bound tyrosine kinase (Barker and 
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Dayhoff, 1982; Roskoski, 2004)，etc. The active products of these genes function to 
inhibit normal apoptotic regulation, reintroduce cells into the cell cycle or to facilitate 
angiogenesis to increase nutrient supply for tumorigenesis. 
1.2.2 Tumor-suppressor genes 
However, cancer is not a result of a single gene mutation of a cell. Our body 
has another system to protect us from cancers. 
Tumor-suppressor genes encode for products that inactivate the oncogene 
products or to induce apoptosis. However when these genes are mutated that the 
encoding proteins lose their function, tumor may arise. These includes the famous p53 
gene that code for a protein that binds DNA, which in turn stimulates another 
production of the p21 protein to interact with a cell division-stimulating protein cdk2. 
Hence to stop downstream cell division (Kim and Deppert, 2003; Levine, 1989). 
Another example is PTEN, which has a roughly same mutation frequency as p53 in 
tumor cases. It codes for a tyrosine phosphatase, which specifically bind 
phosphatidylinositol 3，4，50trisphosphate. This inactivates the PI3-kinase in the insulin 
receptor pathway, and hence inhibited protein synthesis and cell division (Goberdhan 
and Wilson, 2003; Li et al., 1997). These genes are normally switched on to counter act 
the oncogenes. However, if these genes are mutated, in all ways that a mutation can 
form, the activity of the gene product would be reduced, or even abolished. In this case, 
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the oncogenes products are no longer suppressed, and tumorigenesis starts. That means 
tumorigenesis can only be initiated when both the oncogenes and the tumor-suppressor 
genes are mutated. 
1.2.3 Stability genes 
Is anything done to avoid mutations in the genes? Yes, our body has a set of 
stability genes that help maintain the integrity of our genome but do not cause the 
increase of cell proliferation directly. These genes code for enzyme to repair the 
relatively minor mutations, including mismatch repair, nucleotide-excision repair or 
base-excision repair. Examples include breast cancer susceptibility gene 1 and 2 
(BRCAl and BRCA2) encode the proteins that interact with other proteins for DNA 
repair and transcriptional regulation in response to DNA damage. Also they are 
required to maintain the chromosome stability to protect the genome from damage 
(Bishop, 1994; Yoshida and Miki, 2004). There are also other enzymes that control 
chromosome segregation helped maintain the correct chromosome number in each cell. 
If mutations occur in these enzymes, their proper function may be hampered, and the 
DNA mutations in the oncogenes and the tumor-suppressor genes would not be 
repaired (Friedberg, 2003). 
Though tumorigenesis involves the mutation in DNA, not all cancers are 
inheritable. Only germline mutations could be inherited to the next generation. 
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1.2.4 Types of cancer 
Cancer can be divided into 2 groups according to its mobility: 'liquid' and 
'solid' cancer. ‘Liquid’ cancers include different leukemias and lymphomas. The blood 
cells precursors of these cancer cells are initially mobile. Therefore in the human 
cancer cell lines, only these cancer cell lines are in suspension. Cancers developed 
from other origins are 'solid' tumors, composed of epithelial or mesenchymal cells. 
Their cell lines are adherent. 
It has been observed that more mutations are needed to develop solid tumor 
than liquid tumor (Komarova et al., 2003; Nowell, 2002). Also, chromosomal 
translocation is the most commonly found mutation in liquid tumor. And genes 
associated with differentiation are commonly found in them. This maybe due to the 
fact that the leukemias might be originated from haematopoietic cells that are not 
terminally differentiated. 
1.2.5 Cancer therapy 
There are many available therapies to treat cancers. They include therapies at 
tissue level, cellular level and molecular level. Here we focus on the cellular and 
molecular level, to induce apoptosis in cancer cells. 
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1.2.6 Apoptosis 
Apoptosis is a natural process occurs in normal cells. This process helps to 
maintain the number of healthy cells in a biological system. When too many cells are 
produced, apoptosis take place to reduce the cell number to the normal level. When 
cells become old or unhealthy, apoptosis take place to eliminate the cells so that they 
can be replaced by new, healthy cells. 
However, cancer cell can always escape apoptosis to expand. Either their 
proliferation rate is much higher than the apoptosis rate, or their apoptotic pathway is 
hampered, maybe due to mutations in the apoptotic components. This route of cell 
death, compared to necrosis, is a mild one that does not elicit inflammatory response in 
the body. Therefore most of the anti-cancer drugs' target is to induce apoptosis in the 
cancer cells. 
Broadly, there are 2 apoptotic pathways: the death receptor mediated 
pathway (extrinsic pathway) and the mitochondria mediated pathway (intrinsic 
pathway). Both pathways are mediated by cysteine aspartyl specific proteases 
(caspases). Till now, at least 13 mammalian caspases are identified. 
Death receptors are members of the superfamily tumor necrosis factor (TNF) 
receptor. When they receive appropriate signals, such as CD95, TNF-related apoptosis 
inducing ligand-Rl (TRAIL-Rl) and TRAIL-R2, the death receptors attract the 
Fas-associated death domain protein (FADD) (Garg and Aggarwal, 2002; Mirkes, 
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2002). This death-inducing signaling complex (DISC) further draws the procaspase 8 
and procaspase 10. The procaspases are cleaved and activated (Scaffidi et al., 1999; 
Sprick et al.，2002). 
The caspase 8 and 10 are known as initiator caspases, though the function of 
caspase 10 is still unclear. In some cells, the amount of caspase 8 is enough to elicit the 
downstream apoptosis. Whereas in others, caspase 8 cross talks with the mitochondria 
mediated pathway to magnify the apoptotic signal and effect. 
Caspase 8 cleaves the BID molecule so that this cleaved BID is transported 
to the mitochondria for the release of cytochrome c (Gross et al., 1999). It has been 
suggested that the mitochondria permeability is enhanced by caspase 2 to release 
cytochrome c (Troy and Shelanski, 2003). In the cytosol, cytochorme c associates with 
ATP, the apoptotic protease activating factor-1 (APAFl) and procaspase 9 to form an 
apoptosome. Caspase 9 is activated in the apoptosome (Acehan et al., 2002; Chang and 
Yang, 2000). 
Caspase 9 then cleaves and activates the executioner caspases, caspase 3，6 
and 7 (Nicholson and Thomberry, 1997). These executioner caspases cleaved various 
death substrates to give the apoptotic features. The death substrates include the nuclear 
lamins, inhibitors of the endonucleases and other proteins. When the nuclear lamins are 
cleaved, the nucleus shrinks and the chromatin condense. When the inhibitors of the 
endonuclease are cleaved, the endonuclease can restore its activity to cleave the 
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chromosomal DNA, and result in fragmented DNA. When the actin of the cytoskeleton, 
gelsolin and plectin are cleaved, the whole cell shrinks and blebbing occurs. The cell 
finally forms apoptotic bodies for easy engulfment by the phagocytic cells. 
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1.3 Chronic Myelogenous Leukemia (CML) 
In this project, the anti-cancer effect of LC976 on CML cell line, K-562, was 
one of the major foci. 
CML is a type of leukemia signified with a progression of the chronic 
increase in blood leukocytes to the blast crisis. During the blast crisis, immature and 
abnormal myeloid cells flood the bone marrow and the blood. At this stage, the patient 
having the huge amount of immature cells actually have no functional myeloid cells. 
1.3.1 Philadelphia chromosome and BCR-ABL gene 
Over 90% of the CML patients are found associated with the Philadelphia 
chromosome (Fitzgerald et al.，1963; Goh and Swisher, 1964). This is a genetic 
aberration product formed when translocation of the long arms of chromosome 9 and 
22 occurs. In the translocation, the 5' region of the ABL gene is attached to the BCR 
gene to form the aberrant BCR-ABL chimeric gene. 
The ABL gene is originally located on chromosome 9. The natural ABL 
product in human is expressed ubiquitously. It is a nonreceptor tyrosine kinase, which 
tyrosine kinase is an enzyme involved in cell proliferation to phosphorylate 
downstream substrates for the transmission of signals (Kharbanda et al.，1998; 
Konopka et al , 1984). Abl is found both in the nucleus and the cytoplasm. The normal 
Abl function is tightly controlled. It is believed that it is controlled through the motifs 
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in its N-terminal, which is lost to form the Philadelphia chromosome. Apart from the 
tyrosine kinase activity, Abl can also bind DNA (Kipreos and Wang, 1992). In 
hematopoietic cells, the level of Abl decreases as the myeloid cells mature (Wetzler et 
al., 1993). 
The BCR gene is originally located on chromosome 22. Bcr has various 
functional motifs, which make the protein involved in phosphorylation and guanosine 
triphosphate (GTP) binding. This protein is also found located in the nucleus and 
cytoplasm (Dhut et al , 1988; Wetzler et al., 1993), and its level decreases as myeloid 
cells mature. When it is in the nucleus, it can associate with condensed DNA of the 
dividing cells (Wetzler et al , 1995). 
Since the ABL gene is translocated to different regions of the BCR gene, 
ABL-BCR genes of different lengths are formed. The first exon of BCR is found to be 
the common region among the functional isoforms. Serine and threonine kinase 
activities are found in this exon. Its kinase activity also helps propagate cellular signals. 
As the properties of Abl and Bcr are quite similar, it is not difficult to imagine they 
could be 'good partners' when they associate. 
The Bcr-Abl fusion protein is an uncontrolled tyrosine kinase. There are 2 
forms of this protein, and plSS® "^-^ ^^  (Lugo et al , 1990). The former has 
lower tyrosine kinase activity, so it accounts for the chronic leukemia. Whereas the 
latter has a higher tyrosine kinase activity and correspond to acute leukemia. This 
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fusion protein promotes uncontrolled cell proliferation with its uncontrolled tyrosine 
kinase activity. 
1.3.2 Treatment for CML 
Imatinib mesylate (Gleevec) is drug that works effectively against CML. It is 
a specific inhibitor to Bcr-Abl tyrosine kinase to stop cell proliferation (Druker and 
Lydon, 2000)，and the cancer cells can be eliminated by apoptosis. It works well for the 
Philadelphia chromosome positive leukemias. It also works on other cancers 
expressing c-kit and platelet-derived growth factor receptor (PDGF-R). Also, it has 
been reported that it acts against telomerase. (Uziel et al., 2005) 
However some cases of severe cytopenia were observed in the therapy 
(Marin et al , 2003). Also, its use in Philadelphia chromosome negative leukemias is 
still not effective. So it is still needed to develop new drugs to treat CML. 
1.4 Dendritic differentiation of LC976 on K-562 
K-562 is a chronic myelogenous leukemia cell line consists of 
non-terminally differentiated myeloid cells. They are capable for myeloid or erythroid 
cell maturation (Gambari et al., 1984; Han and Minowada, 1980; Olah et a l , 1988; 
Tabilio et al., 1983; Yamada et al., 1983), and can be induced for hemoglobin synthesis 
(Jeannesson et al., 1984; Trentesaux et al., 1989). We found that the extract of 
20 
Chapter 1 Introduction 
Trichosanthes Kirilowii Maxim (LC976) not only induced hemoglobin production in 
K-562 cells, we also observed a morphological differentiation which the cells 
developed cytoplasmic extensions. If we can prove LC976 can induce K-562 cells to 
differentiate into dendritic cells (DCs), it would provide valuable clues to cancer 
vaccine development for chronic myelogenous leukemia. 
1.4.1 Dendritic cells 
Dendritic cell (DC) is one of the antigen presenting cells with cytoplasmic 
extensions, and is part of the immune system. There are generally 3 types of DCs: 
Interdigitating DCs are present in the lymphoid organs, Langerhans cells are found in 
skin, while some other DCs are circulated in the blood stream. 
DC constantly expresses class II MHC molecules in immature form. When the 
cell phagocytoses foreign particles, like bacteria, the particles would be lysed and 
processed into peptides. These foreign peptides then activate the immature class II 
MHC molecules, and are captured in the antigen-binding site of the mature class II 
MHC molecules. Hence, these molecules would be transported to the cell surface for 
the recognition by T helper cells. Once T helper cells recognize the antigen presented 
by the class II MHC molecules, they would be activated to further activate cytotoxic T 
cells or B cells for cell-mediated or humoral immune responses respectively, in order 
to get rid of the foreign particles in the body (Banchereau et al., 2000; Banchereau and 
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Palucka, 2005; Mellman and Steinman, 2001; Steinman, 1991). 
1.4.2 Cancer vaccine development for leukemia 
In the normal physiology, some DCs are responsible to eliminate the 
leukemic cells (Dalgaard et al., 2005; Fujii et al., 1999). Together with dendritic cells' 
excellent antigen-presenting capability, scientists launched various investigations to 
produce anti-leukemia vaccines exploiting dendritic cells. The most common way is to 
prepare DCs by inducing differentiation from peripheral blood mononuclear cells 
(PBMCs) with various cytokines (Pospisilova et al” 2002), then load the DCs with 
various cancer antigens. It has been shown that mice vaccinated by leukemia antigen 
loaded DCs were better protected against leukemia (Colombo et al., 2000; Paczesny et 
al., 2001). By the antigen pulsing techniques to load DCs, studies in cancer vaccine 
against acute lymphoblastic leukemia (Pospisilova et al” 2002), chronic lymphoblastic 
leukemia (Goddard et al., 2003), acute myeloid leukemia (Galea-Lauri, 2002; 
Galea-Lauri et a l , 2002) and chronic myelogenous leukemia (Takahashi et al., 2003). 
However this technique has a weakness that only a limited number of tumor antigens 
can be loaded to the DCs, that limit the immune response aroused against the leukemic 
cells. 
The alternative studies were carried out when the scientists observed some 
chemicals were able to transform the leukemic cells into dendritic cells. In this case, 
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the cell can present its own cancer antigen to its surface to be recognized by the T 
helper cells. Techniques to differentiate acute myeloid leukemia cells (Westers et al., 
2003) and chronic myelogenous leukemia cells (Lindner et al , 2003) were established. 
1.4.3 Dendritic differentiation of K-562 cells 
Here we focus on the reported dendritic differentiation of K-562 cells by the 
phorbol ester PMA (Lindner et al , 2003). PMA was able to induce the differentiation 
of K-562 cells to typical DC morphology, to develop characteristic DC surface markers: 
class II MHC molecules, CD86 and CD40 expression, detected by monoclonal 
antibodies in flow cytometry, and was able to stimulate T cell proliferation equivalent 
to normal monocyte derived DC. Therefore it is believed that K-562 can be 
differentiated into DCs under certain conditions. Therefore it is valuable for us to 
further investigate the effectiveness of LC976 for such DC differentiation. 
1.5 Perspective of the Project: 
Despite the availability of numerous anti-cancer drugs, their 
pharmacokinetics is different in different individuals. With different drug-resistant 
cancers and toxicity to patients, there is still an urgent need to develop new anti-cancer 
drugs. 
It was observed by our labmate that the lead compound LC976 from Herb X 
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could induce anti-proliferative effect in the human CML cell line K-562, when he was 
studying the fetal hemoglobin induction effect of the lead compound. We hence wish to 
study further about the anti-proliferative and cytotoxic effect of LC976 and to evaluate 
whether it could be a potential anti-cancer drug candidate. 
We planned to study and compare the action spectrum of the lead compound 
on different human cell lines. Hence we wanted to study if the LC976 could kill cancer 
cells by inducing the apoptotic pathway. Also, we needed to know its toxicity in 
normal cells. These are the minimum information required to determine the whether 
LC976 could be further developed to be an anti-cancer drug. 
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2.1 Materials 
2.1.1 Chemical and Reagent 
Item Source 
5-dimethylthiazolyl-2)-2, Sigma M2128 
5 -diphenyltetrazolium bromide (MTT) 
Acetone MERCK K27793814 
Acetonitrile LAB-SCAN Analytical Sciences 
C2502 
Dimethyl Sulfoxide (DMSO) Fisher Chemicals D/4121/PB17 
Dulbecco's Modified Eagle Medium (DMEM)~~ GIBCO 12800-017 
Dulbecco's Phospate Buffered Saline (PBS) GIBCO 21600-010 
Ethylenedinitrilotetraacetic acid (EDTA) Sigma ED2SS 
Ethanol (EtOH) MERCK K32295683 
F-12 Nutrient Mixture (Ham) GIBCO 21700-075 
Fetal Bovine Serum (FBS) GIBCO 10270-106 
LC976 ~~ Self Preparation 
Magnesium Chloride (MgCb) Sigma M9272 
Methanol (MeOH) “ F i s h e r Scientific M/4056/17 
Minimum Essential Medium (MEM) GIBCO 41500-034 
Paraformaldehyde (PFA) Sigma P6148 
P I ^ Sigma P9291 
Poly-L-Lysine Sigma P8920 
Propidium Iodide (PI) Sigma P4170 
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PSN Antibiotic Mix (lOOX) IGIBCO 15640-055 
RPMI 1640 Medium GIBCO 23400-021 
Sodium Chloride (NaCl) Sigma S3014 
Table 2.1 Table to show the chemicals and regents used in the project 
2.1.2 Bioassay Kits 
Item Source 
Annexin V-FITC Apoptosis Detection Kit BD Biosciences 556547 
BD A p o A l e r t IM Caspase Assay Plates BD Biosciences 630225 
Cell Proliferation ELISA, BrdU (co lo r ime t r i c )Roche 167229 
Table 2.2 Table to show the bioassay kits used in the project 
2.1.3 Human Cell line 
Item [Description Source 
Urinary Bladder Carcinoma ATCC® HTB-9 
A375* Skin Malignant Melanoma ATCC® CRL-1619 
BUD-8 Skin Fibroblast (Normal) ATCC® CRL-1554 
H ^ Cervix Epithelial Adenocarcinoma ATCC® CCL-2 
HepG2* Hepatocellular Carcinoma ATCC® HB-8065 
HL-60* Acute Promyelocytic Leukemia ATCC® CCL-240 
K-562 Chronic Myelogenous Leukemia ATCC® CCL-243 
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MCF7* iMammary Gland Adenocarcinoma 1ATCC® HTB-22 
MG-63 Osteosarcoma ATCC® C R L - 1 4 2 7 ^ 
PC-3* Prostate Adenocarcinoma ATCC® CRL-1435 
Table 2.3 Table to show the cell lines used in the project 
* Sincerely provided by Dr. Vincent Ooi and Dr. Lawrence C. M. Chiu from the 
Department of Biology, The Chinese University of Hong Kong 
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2.1.4 Lab wares and Equipments 
Item Source 
96-well Culture Plate (Flat Bottom) Nunc 167008 
96-well Culture Plate (U Bottom) Nunc 163320 
Bench-top Centrifuge Eppendorf Centrifuge 5415D 
Biosafety Cabinet Finlead OYR4-1000 
Cell Culture Incubator SHEL-LAB IR2424 
Confocal Microscope BIORAD Radiance 2100 
Coverslips (18x18mm) Kontrollzettel 
Flow Cytometer Beckman Coulter Epics XL-MCL 
Freeze Dryer LABCONCO 77530-01 
Freezer Centrifuge Eppendorf Centrifuge 5402 
Lithium Heparin Tube (4mL) Becton Dickinson 367884 
Microplate Spectrophotometer Molecular Devices Spectra Max 250 
Multi-Purpose Refrigerated Microcentrifuge Beckman Coulter Allegra'^ 21R 
Reverse Phase Extraction Column Waters Sep-Pak Reversed-Phase C18 
Cartridge 
Table 2.4 Table to show the labware and equipment used in the project 
2.2 Extraction of LC976 
2.2.1 Chemical Properties of the Lead Compound 
It was found that a lead compound in Trichosanthes sp possibly has 
anti-cancer effect. The structure of the compound is still unknown. But some of its 
chemical properties are known. It is only partially soluble in water. It dissolves well in 
15% to absolute alcohol. It would precipitate out in polarity higher than 15% EtOH. We 
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tried to remove as much impurities as possible at different polarities without disturbing 
the desired fraction. 
2.2.2 Crude Extraction of Trichosanthes sp 
One thousand and five hundred grams of the fruit of Trichosanthes sp was 
chopped into small pieces and put into 3 l,500mL reagent bottles. Hence, the bottles 
were filled with 95% EtOH until the herbs were totally immersed. The bottles were 
tightly capped and put into the 65�C oven for 72 hours. After 72 hours, the ethanol 
extract of Trichosanthes sp was poured out and its volume was measured. 
The herb extract was evaporated under reduced pressure to about 10% ethanol 
by noticing its bubbling pattern under reduced pressure as well as with the help of the 
alcoholmeter. Hence the extract was adjusted to the final EtOH concentration to about 
35% by adding the appropriate volume of EtOH. This extract was kept at -20°C 
overnight to precipitate the chlorophyll. The extract with the precipitate was centrifuged 
in centrifuge bottles at 30,000xg for 30 minutes. The supernatant was poured out and 
collected, and evaporated under pressure to about 10% EtOH again. Next it was 
adjusted to 25% EtOH and the precipitation procedure was repeated. The precipitation 
was repeated for 1 more time with 15% EtOH. Three rounds of precipitation were to 
ensure all the chlorophyll was removed. There was about 500mL of herb extract at this 
stage. 
2.2.3 Purification by Reversed-Phase Column 
Next the herb extract was further purified with the Reversed-Phase CI8 
Cartridge. The column was used with the vacuum pump setup. The new column was 
washed with 100% MeOH followed by H2O. This rinsing procedure was repeated 2 
times. The column was then conditioned with 30mL of 40% MeOH and was kept moist 
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throughout its use. The herb extract obtained above was first loaded into the column, 
and next washed with different solvents as described in Table 2.4, to remove the 
unwanted components with polarity different from our desired fraction. After washing, 
our desired compounds were retained in the column. They were then eluted with 60% 
MeOH. The purification steps were cycled as in Table 2.4 until all the herb extract was 
purified. 
Step I Loading iFiltrate Fraction Collected 
1 lOmLherb extract 10mL40% MeOH (2nd) 
2 15mL40% MeOH (1st) 5mL40%MeOH (2nd) 
+ lOmL extracting EtOH 
3 15mL40%MeOH (2nd) 15mL40% MeOH (1st) 
4 15mL40%MeOH (3rd) 15mL40% MeOH (2nd) 
5 15mL40%MeOH (4th) 15mL 40% MeOH (3rd) 
6 15mL 60% MeOH (1st elution) 15mL40%MeOH (4th) 
7 15mL 60% MeOH (2nd elution) 15mL 60% MeOH (1st elution) 
8 15mL 60% MeOH (3rd elution) 15mL 60% MeOH (2nd elution) 
9 15mL 100% MeOH (1st) 15mL 60% MeOH (3rd elution) 
T o 15mL 100% MeOH (2nd) 15mL 100% MeOH (1st) 
n 15mL 100% MeOH (3rd) 15mL 100% MeOH (2nd) 
n 15mL 100% MeOH (4th) 15mL 100% MeOH (3rd) 
n 15mL 100% acetonitrile 15mL 100% MeOH (4th) 
H 15mLmilli-Q HzOClst) 15mL 100% acetonitrile 
I s 15mLmilli-Q H2O (2nd) 15mLmilli-Q H2O (1st) 
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16 |l5mLmilli-Q H2O (3rd) |l5mLmilli-Q H2O (2nd) 
n 15mLmilli-Q H2O (4th) 15mLmilli-Q H2O (3rd) 
T8 15mL40%MeOH(lst) 15mLmilli-Q H2O (4th) 
19 15mL40%MeOH (2nd) 15mL40% MeOH (1st) 
1 Back to Step 1 
Table 2.5 Steps to purify Trichosanthes sp. extract with re versed-phase 
column 
2.2.4 Lyophilization and Preparation of LC976 
After purification by the reverse phase column, our collected fraction was 
evaporated at reduced pressure to a smaller volume of around 30mL. Hence this extract 
was lyophilized for 3 days and the dried powder containing the lead compound was 
weighed. Finally the power was dissolved in 4mL absolute EtOH and filtered for culture 
use. 
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2.3 Anti-Proliferation Effect of LC976 on Human Cell Lines 
2.3.1 Maintenance of Cell Lines 
The MTT cell viability assay and BrdU cell proliferation ELISA were 
performed on the following 8 human cancer cell lines and 1 human normal cell line: 
Chronic myelogenous leukemia K562, acute promyelocytic leukemia HK-60, 
urinary bladder carcinoma 5637, cervix epithelial adenocarcinoma Hela, skin malignant 
melanoma A375, osteosarcoma MG-63, mammary gland adenocarcinoma MCF7, 
prostate adenocarcinoma PC-3, hepatocellular carcinoma Hep-G2 and normal skin 
fibroblast BUDS. 
K562, HL-60, 5637 and Hep-G2 were cultured with RPMI 1640 medium. 
Hela, MG-63, MCF7 and BUDS were maintained with EMEM. A375 was maintained 
with DMEM and PC-3 was maintained with F-12 Nutrient Mixture (Ham). All media 
used were completed with 10% FBS, IX PSN. All cell lines were cultured in incubators 
of 37°C，5% CO2 level and 95% humidity. 
2.3.2 MTT Assay 
LC976 was added to the first well of a 96-well culture plate containing 200|aL 
medium. Then 2-fold serial dilution was performed, to the subsequent wells containing 
lOO i^L medium, for 22 dilutions. Serial dilution was performed horizontally across the 
96-well culture plate, for 2 rows, so that the first well LC976 concentration became 
618.75^g/mL upon addition of 100 i^L cell, and the concentration were halved in the 
next well. The last 2 wells were left for no-drug control. 
The number of cells being seeded to each well plate was determined 
according to the maximum and optimal cell density of the cell lines. The number of 
cells seeded for each cell line are: 4 x 10^ cells for K-562, 4 x 10^ cells for HL-60, 2 x 
10^ cells for 5637，1.5 x 10^ cells for Hela, 1 x 10^ cells for A375, 5 x 10^ cells for 
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MG-63, 8 X 102 cells for MCF7, 1 x 10^ cells PC-3 and 1 x 10^ cells for BUD-8. 
For suspension cell line, K-562 and HL-60 cells were immediately added to 
the LC976 dilutions, to make up to a total volume of 200|a,L for each well. The cells 
were cultured in 96-well U-shape bottom culture plate. 
For adherent cell lines, 5637, Hela, A375，MG-63, MCF7, PC-3 and BUD8, 
cells were seeded in lOOjiL medium without LC976 addition and incubated for 24 hours. 
Then LC976 dilutions were prepared as mentioned above and added to the cells. The 
cells were cultured in 96-well flat-bottom culture plate. 
All dilution procedures were performed with the medium according to the cell 
lines' need as mentioned above. Upon addition of LC976, the culture plate was 
incubated for 4 cell cycles, ranged from 3 days to 5 days, with the cell cycle for each 
cell line deduced prior to the experiment. For the cell lines with 4 cell cycles more than 
5 days, they were restrained to 5 days. Also, for all cell lines, triplicate assays were set 
up for more accurate results. 
After incubation, MTT assay was performed. 
MTT solution (5mg/mL) was prepared by dissolving MTT powder in PBS, 
filtered through 0.03 ^ im filter for use. 20|iL of the MTT solution was added to each well, 
then incubated at 37°C, 5% CO2 level and 95% humidity for 4 hours. Afterwards, the 
culture plate was centrifuged at 1,000 rpm for 10 minutes and the medium were 
removed carefully by suction. 150fiL of DMSO was added to each well to dissolve the 
cell membrane and the blue formazon crystal formed by mitochondrial metabolism. OD 
measurement was then performed at 570nm. (Mosmann, 1983; Zhang et a l , 2003) 
The results were analyzed with the computer software Prism®. Percentage of 
Proliferation was calculated by: 
( O D � of LC976 - treated group) x 100% 
O D 5 7 0 of no drug control group 
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2.3.3 BrdU Cell Proliferation ELISA 
LC976 dilution and cell seeding protocol was the same as the MTT cell 
viability assay, except that the cell lines assayed were different. The suspension cell 
lines used in BrdU cell proliferation ELISA included K562 and HL-60, while the 
adherent cell lines included 5637，Hela, MG-63, MCF7, PC-3，Hep-G2 and BUD8. In 
this assay, all cell lines were cultured in 96-well flat bottom culture plates. 
After 3 cell cycles of incubation, BrdU cell proliferation ELISA was 
performed according to the Instruction Manual came along with the Cell Proliferation 
ELISA, BrdU (colorimetric) kit from Roche. (Gratzner, 1982; Porstmann et al., 1985; 
Vanderlaan and Thomas, 1985) 
Twenty [xL of lOX BrdU labeling solution was added to each well of the plate 
and incubated for 6 hours at 37°C, 5% CO2 level and 95% humidity. Next, the plate was 
centrifuged at lOOOrpm for 10 minutes. The culture medium was then drawn carefully 
away by suction and the plate was dried at 65°C for 1 hour. Then, 200)aL of FixDenat 
solution was added to each well, incubated for 30 minutes at room temperature. Hence, 
the FixDenat solution was tapped off, and lOO i^L anti-BrdU-POD working solution was 
added to each well. After this, the plate was incubated for 90 minutes at room 
temperature. Afterwards, the anti-BrdU-POD working solution was tapped off and all 
wells were washed three times with 200}iL IX Washing solution. Finally, lOO i^L of the 
Substrate solution was added to each well, incubated for 10 minutes, and then OD 
measurement was carried out at 370nm. 
The results were analyzed with the computer software Prism®.Percentage of 
Proliferation was calculated by: 
(OD巡 of LC976 - treated group) x 100% 
O D 3 7 0 of no drug control group 
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2.4 Apoptosis Induction on K-562 
2.4.1 PI Staining 
From the BrdU anti-proliferation ELISA, the EC50 to inhibit K-562 
proliferation is 65fig/mL. With reference to the EC50 value, K-562 was incubated with 
4 concentrations of LC976 (260|^g/mL, 130|ag/mL, 65|^g/mL, 33|j.g/mL) and 1 control 
without drug treatment. These LC-976 treated cells were incubated for 2 and 3 cell 
cycles, respectively 36 hours and 54 hours. The cells were cultured in 6-well culture 
plates, with each well holding 2 mL cell culture. Incubation was carried out in an 
incubator of 37°C, 5% CO2 level and 95% humidity. By the end of the incubation period, 
cells were at a density of around 1 x 10^ cells/mL. 
Before the staining procedure, poly-L-lysine coated coverslips and 2 reagents 
were prepared. 
First, poly-L-lysine coated coverslips were prepared. It was done by 
immersing the coverslips in absolute ethanol followed by acetone. Then they were 
air-dried, and poly-L-lysine solution (0.01% in water) was put on the coverslips and 
allowed to stand at room temperature for 30 minutes. Afterwards, the excessive 
poly-L-lysine solution was poured off, washed with distilled water and air-dried. 
Second, lOX CSK solution was prepared with distilled water to lOOmM 
PIPES pH6.8 (adjusted with ION NaOH)，IM NaCl, 31mM MgCh and 20mM EDTA. 
Third, 3.7% PFA solution was prepared by dissolving PFA in IX CSK 
solution, diluted from lOX solution by PBS. The solution was then incubated at 65�C 
for 30 mintues for dissolution. 
PI staining was then performed (Chakrabarty et al.，2002; Tas and Westemeng, 
1981). 
2 X 10^ K-562 cells were harvested and washed once in PBS. Hence, they 
were resuspended in SOO i^L of PBS and put on poly-L-lysine coated coverslips for 30 
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minutes at 4°C. Afterwards, the unbound cells were gently poured away. The coverslips 
were carefully washed once with PBS. The cells were then fixed in 3.7% PFA for 10 
minutes at room temperature. Then, they were washed 3 times with CSK. Afterwards, 
0.2% Triton X-100 in CSK was added to the coverslips for 5 minutes at room 
temperature, followed by washing with PBS once. Hence, PI solution (l^ig/mL PI in 
PBS) was added to stain the cells for 10 minutes at room temperature. Next, the PI 
staining solution was washed off with PBS, and the stained cells on the coverslips were 
mounted onto the glass slides with nail polish and cellotape. Finally the slides were 
observed under the confocal microscope with laser emitting at 488nm. 
2.4.2 Annexin V-FITC FACS Analysis 
K-562 was incubated at 260|ag/mL LC976 concentration for different time 
interval, 5 minutes, 4 hours, 16 hours and 24 hours, together with a no-drug control, to 
access the apoptosis induction effect of LC976 on K562. The cells were cultured in an 
incubator of37°C, 5% CO2 level and 95% humidity. By the end of the incubation period, 
1 X 106 cells of each sample were harvested for Annexin V-FITC and PI staining 
following the Staining Protocol came along with the Annexin V-FITC Apoptosis 
Detection Kit of BD Biosciences (van Engeland et al., 1996; Vermes et al., 1995). 
1 X 10^ cells were harvested and washed twice with cold PBS, and then 
resuspended in ImL of IX Annexin V Binding Buffer. Next, \50\xL of the cell 
suspension (1.5 x 10^ cells) was transferred to a new microfuge tube and 7.5^L of 
Annexin V-FITC and 7.5faL of PI solution were added to it. The cells were gently mixed 
by flicking and incubated for 15 minutes at room temperature in the dark. Finally 600}iL 
of IX Annexin V Binding Buffer and flow cytometry analysis was carried out within 1 
hour. The data of FACS were represented in the dot-plot format by the computer 
software Expo32 ADC. 
36 
Chapter 2 Materials and Methods 
For optimization of the conditions of the flow cytometer, 2 controls were set; 
they were cells stained only with PI and cells stained only with Annexin V. 
2.4.3 Caspase Activation 
K-562 was incubated at 260|ig/mL LC976 concentration and no-drug 
condition for 4 cell cycles (3 days), each group with 3 replicates to give statistically 
valid results. The cells were cultured in an incubator of 37�C, 5% CCh level and 95% 
humidity. By the end of the incubation, caspase activities of K562 were accessed 
following the User Manual of BD ApoAlert'^'^ Caspase Assay Plates from BD 
Biosciences. 
For each replicate of the group, 2 x 10^  cells were harvested by centrifugation 
at 400rpm for 5 minutes in microcentrifuge tubes. The cell pellet was then resuspended 
in 50|^L of iced IX Cell Lysis Buffer, and incubated on ice for 10 minutes. Next, the cell 
lysate was centrifuged at maximum spend for 5 minutes at 4°C. The supernatant was 
then transferred to a new microcentrifuge tube. At the same time, 50fiL of 2X Reaction 
Buffer/DTT Mix was added to the BD ApoAlert™ Caspase Assay Plate, sealed with 
Parafilm and incubated at 37°C for 5 minutes. After centrifugation, 50|aL of the cell 
lysate was added to the appropriate well of the assay plate. The plate was then sealed 
with Parafilm again and incubated at 37°C for 2 hours. Finally, the plate was analyzed at 
460nm. The results were analyzed with the computer software Prism®. The OD460 
readings of the LC976-treated group were normalized with the control group as the 
percentage change in caspase activities. Percentage change in caspase activity (%) 
= O D ^ of LC976 treated K-562 x 100% 
Mean OD460 of the control K-562 
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2.5 Effect on Normal Human Lymphocytes 
2.5.1 Preparation of Human Normal Lymphocytes 
Twenty mL peripheral blood from a volunteer with healthy medical history 
was drawn into 5 heparin tubes. The tubes containing the blood were inverted several 
times once the blood was drawn, to mix with the heparin to prevent blood clotting. Then, 
the same volume of PBS was added to dilute the blood. Afterwards, lymphocyte 
isolation was carried out with Ficoll-Paque Plus reagent for human blood, following the 
Instructions manual came along with the reagent from Amersham Biosciences 
(Krotlinger, 1974; Perper et al., 1968). 
Three mL of Ficoll-Paque Plus was first added to 1 centrifuge tube. Then 4mL 
of the diluted blood was carefully layered onto it. Hence, the tubes were centrifuged at 
400xg for 40 minutes at 19�C. Upon centrifugation, the mixture was separated into 4 
visible layers. The upper layer containing the plasma was removed. Next, the milky 
lymphocyte layer was transferred into a new centrifuge tube. Afterwards, the 
lymphocytes were washed twice with 6mL of PBS per centrifuge tube. Finally the 
lymphocytes were resuspended in complete RPMI 1640 medium at a cell density of 1 x 
106 cells/mL. The cells were then used for various assays, and they were maintained at 
37°C, 5% CO2 level and 95% humidity. 
2.5.2 MTT Cell Viability Assay 
The procedure was similar to MTT assay for the human cancer cell lines in 
2.2.2. The incubation time of the normal lymphocytes was 2 days, and 8 x lO* cells 
were seeded to each well of the 96-well culture plate. The reduction of incubation time 
was because normal lymphocytes do not replicate and have limited life span of around 7 
days. Whereas the large number of cells seeded was due to the inability of the normal 
lymphocytes to proliferate. 
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2.5.3 PI Staining 
Normal human lymphocytes were incubated at 260|j.g/mL LC976 
concentration for 2 days at 37°C, 5% CO2 level and 95% humidity. After the incubation 
period, PI staining was performed according to the procedure mentioned previously in 
2.3.1 
2.5.4 Annexin V-FITC FACS Analysis 
Normal human lymphocytes were incubated at 260jag/mL LC976 
concentration for 24 hours at 37�C, 5% CO2 level and 95% humidity. Hence the 
Annexin V-FITC FACS analysis was performed according to the procedure described in 
Materials and Methods 2.4.2. 
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3.1 Extraction of LC976 
One thousand and five hundred grams of the fruit of Trichosanthes sp. was 
extracted with 95% EtOH. Chlorophylls and other pigments were precipitated and 
removed. Hence the partially purified extract was further purified with reversed-phase 
columns. The volume of purified fraction containing the lead compound was reduced 
and lyophilized for 3 days. The purification steps are described in detail in Materials 
and Methods 2.1. Finally, 0.495g of LC976 was obtained after lyophilization, and was 
dissolved in 4mL of 95% EtOH. The final concentration of the LC976 solution is 
123.75|ag/mL. This solution was then filtered through 0.22fiL filter and was used in the 
subsequent cell culture assays. 
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3.2 LC976 Inhibited Proliferation of Human Cell Lines 
3.2.1 MTT Assay 
MTT assay was used to determine the anti-proliferation effect of LC976 on 
the human cancer cell lines: K-562, HL-60, 5637，Hela, A375, MG-63, MCF7 and PC-3 
as well as one normal cell line BUD-8. The cells were incubated in 96-well culture 
plates and treated with different concentrations of LC976. The number of cells seeded to 
each well of the 96-well culture plates for each cell line are: 4 x 10�cells for K-562, 4 x 
10^ cells for HL-60, 2 x 10^ cells for 5637, 1.5 x 10^ cells for Hela, 1 x 10^ cells for 
A375, 5 X 10^ cells for MG-63, 8 x 10^ cells for MCF7, 1 x 10^ cells PC-3 and 1 x 10^ 
cells for BUD-8. For the adherent cell lines (all except K-562 and HL-60), cells were 
seeded and incubated for 24 hours before addition of LC976 as described in Methods 
and Materials 2.3.2. 
The percentage of proliferation of the cells was plotted against the log of 
concentration of LC976 using the computer software Prism®, with non-linear regression. 
(Figures 3.1 to 3.9) 
From the EC50 values, LC976 has the highest anti-proliferation effect on 
MG-63 and the lowest anti-proliferation effect on MCF-7. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (MTT Assay) 
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Figure 3.1 Anti-proliferation effect of LC976 on K-562 cells (MTT Assay). 
4 X 10^ K-562 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37°C, 5% CO2 level and 95% humidity for 72 hours. The 
MTT assay was then performed as described in Materials and Methods 2.3.2. Untreated 
K-562 cells seeded in the same plate were used as the control. The OD570 reading of the 
treated cells was normalized as the percentage of proliferation, and plotted against the 
log of LC976 concentration with the computer software Prism®. The assay was 
performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (MTT Assay) 
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Figure 3.2 Anti-proliferation effect of LC976 on HL-60 cells (MTT Assay). 
4 X 103 HL-60 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37�C，5% CO2 level and 95% humidity for 100 hours. The 
MTT assay was then performed as described in Materials and Methods 2.3.2. Untreated 
HL-60 cells seeded in the same plate were used as the control. The O D 5 7 0 reading of the 
treated cells was normalized as the percentage of proliferation, and plotted against the 
log of LC976 concentration with the computer software Prism®. The assay was 
performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (MTT Assay) 
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Figure 3.3 Anti-proliferation effect of LC976 on 5637 cells (MTT Assay). 
2 X 10^ 5637 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37�C，5% CO2 level and 95% humidity for 120 hours. The 
MTT assay was then performed as described in Materials and Methods 2.3.2. Untreated 
5637 cells seeded in the same plate were used as the control. The O D 5 7 0 reading of the 
treated cells was normalized as the percentage of proliferation, and plotted against the 
log of LC976 concentration with the computer software Prism®. The assay was 
performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (MTT Assay) 
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Figure 3.4 Anti-proliferation effect of LC976 on Hela cells (MTT Assay). 
1.5 X 10^ Hela cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37°C, 5% CO2 level and 95% humidity for 120 hours. The 
MTT assay was then performed as described in Materials and Methods 2.3.2. Untreated 
Hela cells seeded in the same plate were used as the control. The O D 5 7 0 reading of the 
treated cells was normalized as the percentage of proliferation, and plotted against the 
log of LC976 concentration with the computer software Prism®. The assay was 
performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
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Figure 3.5 Anti-proliferation effect of LC976 on A375 cells (MTT Assay). 
1 X 10^ A375 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37�C，5% CO2 level and 95% humidity for 120 hours. The 
MTT assay was then performed as described in Materials and Methods 2.3.2. Untreated 
A375 cells seeded in the same plate were used as the control. The O D 5 7 0 reading of the 
treated cells was normalized as the percentage of proliferation, and plotted against the 
log of LC976 concentration with the computer software Prism®. The assay was 
performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
g 125-1 
0 100- • T ^ ^ ^ Best-fit values 
•云 BOTTOM 0.0 
S3 75- ^ TOP 100.0 
；= 〜 LOGEC50 -0.02346 
2 50- 1 HILLSLOPE -1.187 
t \ EC50 0.9474 
1 25-
§ 0 1 1 1 
a -5.0 -2.5 0.0 2.5 5.0 
a! -25 Log LC976 Cone (^ig/mL) 
Figure 3.6 Anti-proliferation effect of LC976 on MG-63 cells (MTT Assay). 
5 X 10^ MG-63 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 3TC, 5% CO2 level and 95% humidity for 120 hours. The 
MTT assay was then performed as described in Materials and Methods 2.3.2. Untreated 
MG-63 cells seeded in the same plate were used as the control. The O D 5 7 0 reading of 
the treated cells was normalized as the percentage of proliferation, and plotted against 
the log of LC976 concentration with the computer software Prism®. The assay was 
performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
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Figure 3.7 Anti-proliferation effect of LC976 on MCF-7 cells (MTT Assay). 
8 X 102 MCF-7 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37°C, 5% CO2 level and 95% humidity for 120 hours. The 
MTT assay was then performed as described in Materials and Methods 2.3.2. Untreated 
MCF-7 cells seeded in the same plate were used as the control. The OD570 reading of 
the treated cells was normalized as the percentage of proliferation, and plotted against 
® 
the log of LC976 concentration with the computer software Prism . The assay was 
performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
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Figure 3.8 Anti-proliferation effect of LC976 on PC-3 cells (MTT Assay). 
1 X 10^ PC-3 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37�C, 5% CO2 level and 95% humidity for 120 hours. The 
MTT assay was then performed as described in Materials and Methods 2.3.2. Untreated 
P C - 3 cells seeded in the same plate were used as the control. The O D 5 7 0 reading of the 
treated cells was normalized as the percentage of proliferation, and plotted against the 
log of LC976 concentration with the computer software Prism®. The assay was 
performed in triplicate. 
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Figure 3.9 Anti-proliferation effect of LC976 on BUD-8 cells (MTT Assay). 
1 X 10^ BUD-8 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37�C，5% CO2 level and 95% humidity for 120 hours. The 
MTT assay was then performed as described in Materials and Methods 2.3.2. Untreated 
B U D - 8 cells seeded in the same plate were used as the control. The O D 5 7 0 reading of 
the treated cells was normalized as the percentage of proliferation, and plotted against 
the log of LC976 concentration with the computer software Prism®. The assay was 
performed in triplicate. 
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Table 3.1 Comparison of EC50 of Different Human Cell Lines in Response to 
the Anti-Proliferation Effect of LC976. 
Cell Line Origin EC50 (^ig/mL) 
MCF-7 Mammary Gland Adenocarcinoma 97.150 
K-562 Chronic Myelogenous Leukemia 30.970 
HL-60 Acute Promyelocytic Leukemia 7.169 
Hela Cervix Epithelial Adenocarcinoma 4.245 
BUD-8 Normal Skin Fibroblast 2.680 
A375 Skin Malignant Melanoma 2.579 
PC-3 Prostate Adenocarcinoma 2.472 
5637 Urinary Bladder Carcinoma 2.065 
MG-63 Osteosarcoma 0.947 
The EC50 values were calculated from their corresponding percentage of proliferation 
curves. 
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3.2.2 BrdU Cell Proliferation ELISA 
BrdU Cell Proliferation ELISA was performed to determine the 
anti-proliferation effect of LC976 on the human cancer cell lines: K-562, 5637, Hela, 
MG-63, MCF7, PC-3, HepG2, as well as one normal cell line BUD-8. The cells were 
incubated in 96-well culture plates and treated with different concentrations of LC976. 
The number of cells seeded to each well of the 96-well culture plates for each cell line 
are: 4 x 10^ cells for K-562, 2 x 10^  cells for 5637, 1.5 x 10^  cells for Hela, 5 x 10^ cells 
for MG-63, 8 x 10^ cells for MCF7, 1 x 10^  cells PC-3, 2 x 10^  cells for HepG2 and 1 x 
10^ cells for BUD-8. For the adherent cell lines (all except K-562), cells were seeded 
and incubated for 24 hours before addition of LC976 as described in Methods and 
Materials 2.3.2. 
The percentage of proliferation of the cells was plotted against the log of 
concentration of LC976 using the computer software Prism®, with non-linear regression. 
(Figures 3.10a to 3.17) 
From the EC50 values, LC976 has the highest anti-proliferation effect on 
PC-3 and the lowest anti-proliferation effect on MCF-7. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
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Figure 3.10a Anti-proliferation effect of LC976 on K-562 cells (BrdU Assay). 
4 X 103 K-562 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37�C, 5% CO2 level and 95% humidity for 72 hours. The 
BrdU Cell Proliferation ELISA was then performed as described in Materials and 
Methods 2.3.2. Untreated K-562 cells seeded in the same plate were used as the control. 
The O D 3 7 0 reading of the treated cells was normalized as the percentage of proliferation, 
and plotted against the log of LC976 concentration with the computer software Prism®. 
The assay was performed in triplicate. 
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Figure 3.10b Anti-proliferation effect of LC976 on K-562 cells (BrdU Assay). 
4 X 10^ K-562 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37�C，5% CO2 level and 95% humidity for 72 hours. The 
BrdU Cell Proliferation ELISA was then performed as described in Materials and 
Methods 2.3.2. Untreated K-562 cells seeded in the same plate were used as the control. 
The O D 3 7 0 reading of the treated cells was normalized as the percentage of proliferation, 
and plotted against the log of LC976 concentration with the computer software Prism®. 
The assay was performed in triplicate. 
54 
Chapter 3 Results 
Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
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Figure 3.11 Anti-proliferation effect of LC976 on 5637 cells (BrdU Assay). 
2 X 10^ 5637 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37°C, 5% CO2 level and 95% humidity for 72 hours. The 
BrdU Cell Proliferation ELISA was then performed as described in Materials and 
Methods 2.3.2. Untreated 5637 cells seeded in the same plate were used as the control. 
The O D 3 7 0 reading of the treated cells was normalized as the percentage of proliferation, 
and plotted against the log of LC976 concentration with the computer software Prism®. 
The assay was performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 c e l l s (BrdU Assay) 
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Figure 3.12 Anti-proliferation effect of LC976 on Hela cells (BrdU Assay). 
1.5 X 10^ Hela cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37�C, 5% CO2 level and 95% humidity for 72 hours. The 
BrdU Cell Proliferation ELISA was then performed as described in Materials and 
Methods 2.3.2. Untreated Hela cells seeded in the same plate were used as the control. 
The O D 3 7 0 reading of the treated cells was normalized as the percentage of proliferation, 
and plotted against the log of LC976 concentration with the computer software Prism®. 
The assay was performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
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Figure 3.13 Anti-proliferation effect of LC976 on MG-63 cells (BrdU Assay). 
5 X 10^ MG-63 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 3TC, 5% CO2 level and 95% humidity for 72 hours. The 
BrdU Cell Proliferation ELISA was then performed as described in Materials and 
Methods 2.3.2. Untreated MG-63 cells seeded in the same plate were used as the control. 
The O D 3 7 0 reading of the treated cells was normalized as the percentage of proliferation, 
and plotted against the log of LC976 concentration with the computer software Prism®. 
The assay was performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
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Figure 3.14a Anti-proliferation effect of LC976 on MCF-7 cells (BrdU Assay). 
8 X 10^ MCF-7 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37�C，5% CO2 level and 95% humidity for 72 hours. The 
BrdU Cell Proliferation ELISA was then performed as described in Materials and 
Methods 2.3.2. Untreated MCF-7 cells seeded in the same plate were used as the control. 
The O D 3 7 0 reading of the treated cells was normalized as the percentage of proliferation, 
and plotted against the log of LC976 concentration with the computer software Prism®. 
The assay was performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
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Figure 3.14b Anti-proliferation effect of LC976 on MCF-7 cells (BrdU Assay). 
8 X 10^ MCF-7 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37�C，5% CO2 level and 95% humidity for 72 hours. The 
BrdU Cell Proliferation ELISA was then performed as described in Materials and 
Methods 2.3.2. Untreated MCF-7 cells seeded in the same plate were used as the control. 
The O D 3 7 0 reading of the treated cells was normalized as the percentage of proliferation, 
and plotted against the log of LC976 concentration with the computer software Prism®. 
The assay was performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
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Figure 3.15 Anti-proliferation effect of LC976 on PC-3 cells (BrdU Assay). 
1 X 10^ PC-3 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37°C, 5% CO2 level and 95% humidity for 72 hours. The 
BrdU Cell Proliferation ELISA was then performed as described in Materials and 
Methods 2.3.2. Untreated PC-3 cells seeded in the same plate were used as the control. 
The O D 3 7 0 reading of the treated cells was normalized as the percentage of proliferation, 
and plotted against the log of LC976 concentration with the computer software Prism®. 
The assay was performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
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Figure 3.16 Anti-proliferation effect of LC976 on HepG2 cells (BrdU Assay). 
2 X 10^ HepG2 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37°C, 5% CO2 level and 95% humidity for 72 hours. The 
BrdU Cell Proliferation ELISA was then performed as described in Materials and 
Methods 2.3.2. Untreated HepG2 cells seeded in the same plate were used as the control. 
The O D 3 7 0 reading of the treated cells was normalized as the percentage of proliferation, 
and plotted against the log of LC976 concentration with the computer software Prism®. 
The assay was performed in triplicate. 
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Anti-Proliferation Effect of LC976 
on K-562 cells (BrdU Assay) 
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Figure 3.17 Anti-proliferation effect of LC976 on BUD-8 cells (BrdU Assay). 
1 X 10^ BUD-8 cells per well in 96-well culture plate were incubated with different 
concentrations of LC976 at 37�C，5% CO2 level and 95% humidity for 72 hours. The 
BrdU Cell Proliferation ELISA was then performed as described in Materials and 
Methods 2.3.2. Untreated BUD-8 cells seeded in the same plate were used as the control. 
The O D 3 7 0 reading of the treated cells was normalized as the percentage of proliferation, 
and plotted against the log of LC976 concentration with the computer software Prism®. 
The assay was performed in triplicate. 
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Table 3.2 Comparison of the Mean EC50 of Different Human Cell Lines in 
Response to the Anti-Proliferation Effect of LC976. 
Cell Line Origin Mean EC50 (jig/mL) 
MCF-7 Mammary Gland Adenocarcinoma 138.75 
HepG2 Hepatocellular Carcinoma 128.5 
K-562 Chronic Myelogenous Leukemia 65.07 
Hela Cervix Epithelial Adenocarcinoma 4.201 
BUD-8 Normal Skin Fibroblast 3355 
MG-63 Osteosarcoma 3.290 
5637 Urinary Bladder Carcinoma 1.789 
PC-3 Prostate Adenocarcinoma 1.419 
The EC50 values were calculated from their corresponding percentage of proliferation 
curves. 2 sets of data were obtained for K-562 and MCF-7, hence the mean of the EC50 
were calculated. 
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3.3 LC976 Induced Apoptosis in K-562 Cells 
3.3.1 PI Staining 
After the incubation of K-562 with different LC976 concentrations 
(260|j.g/mL, 130fj,g/mL, 65|j.g/mL, 33|j.g/mL), with 1 no-drug control for 36 hours and 
54 hours, the cells were fixed and stained with PL After staining, the slides were 
mounted onto the slides with nail polish and cellotape. Then the slides were observed 
under the confocal microscope with laser emission at 488nm. 
K-562 cells treated with LC976 for 54 hours are shown in Figure 3.3.1.1a-l， 
while those treated for 36 hours are shown in Figure 3.3.1.2a-j 
Apoptotic cells with condensed and segregated nucleus were observed in 
K-562 cells incubated with higher LC976 concentrations. At 260|ig/mL and 130|Lig/mL, 
both incubation periods gave similar effect of apoptosis induction in K562. However, at 
65|j.g/mL, apoptosis was shown only in 54 hours, that is in longer incubation period. 
At low concentration of LC976 (33|Lig/mL), apoptotic cell was rarely found, 
but cytoplasmic extensions were formed on K-562 cells. Untreated K-562 cells 
(0|j,g/mL) did not show the apoptotic features. They remained spherical without 
condensed nucleus. 
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Figure 3.18a-l PI staining to show apoptosis of K562 treated with LC976 for 54 
hours. 
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K-562 cells were incubated with different concentrations of LC976 for 54 hours (3 cell 
cycles). They were then fixed and stained with PI according to Materials and Methods 
2.4.1. The stained cells were observed under the confocal microscope with laser 
excitation at 488nin. Both the fluorescence field and the bright field are shown, a and b: 
K562 cells treated with 260|ig/niL LC976, fluorescence and bright fields respectively, c 
and d: K562 cells treated with 130^g/mL LC976, fluorescence and bright fields 
respectively, e and f: K562 cells treated with 65|ag/mL LC976, fluorescence and bright 
field respectively, g and h: K562 cells treated with 33|ag/mL LC976, fluorescence and 
bright fields respectively, i and j: Another field to show K562 cells treated with 
33|ag/mL LC976，fluorescence and bright fields respectively, k and 1: Untreated K562 
cells used as the control, fluorescence and bright fields respectively. 
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Figure 3.19a-j PI staining to show apoptosis of K562 treated with LC976 for 36 
hours. 
K-562 cells were incubated with different concentrations of LC976 for 36 hours (2 cell 
cycles). They were then fixed and stained with PI according to Materials and Methods 
2.4.1. The stained cells were observed under the confocal microscope with laser 
excitation at 488nm. Both the fluorescence field and the bright field are shown, a and b: 
K562 cells treated with 260|ag/mL LC976, fluorescence and bright fields respectively, c 
and d: K562 cells treated with 130|ag/mL LC976, fluorescence and bright fields 
respectively, e and f: K562 cells treated with 65|^g/mL LC976, fluorescence and bright 
fields respectively, g and h: K562 cells treated with 33|ag/mL LC976, fluorescence 
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and bright fields respectively, i and j: Untreated K-562 cells used as the control, 
fluorescence and bright fields are shown respectively. 
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3.3.2 Annexin V-FITC FACS Analysis 
K-562 cells were treated with 260|ag/mL of LC976 for 5 minutes, 4 hours, 16 
hours and 24 hours. Untreated K-562 cells were used as the control. The cells were 
cultured in an incubator of 37°C, 5% CO2 level and 95% humidity. By the end of the 
incubation period, 1.5 x 10^  cells of each sample were stained with Annexin V-FITC 
and PI for FACS analysis as described in Materials and Methods 2.4.2. The data of 
FACS were represented in the dot-plot format by the computer software Expo32 ADC. 
(Figure 3.20a to e) 
LC976 was able to induce apoptosis in K-562 cells shortly after it was added 
to the cells. Apoptosis started 4 hours after LC976 addition and continued throughout 
the next 24 hours. The longer the incubation period, the higher the proportion of cells 
were apoptotic, and more disrupted cells were found. 
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Figure 3.20a-e Annexin V-FITC FACS Dot-plot to show apoptosis of 
K-562 induced by LC976. K-562 cells were treated with 260^g/mL LC976 for 
different time periods. 1.5 x 10^ cells were stained with Annexin V-FITC and PI as 
described in Materials and Methods 2.3.2. FACS analysis was then performed and the 
data were analyzed by the computer software Expo32 ADC. The percentage of cells 
gated into each region of the dot-plot was shown in the table, a: Untreated K-562 cells 
used as the control, b: K-562 cells treated for 5 minutes, c: K-562 cells treated for 4 
hours, d: K-562 cells treated for 16 hours, e: K-562 cells treated for 24 hours. 
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3.3.3 Caspase Activation 
K-562 cells were incubated at 260|ag/mL LC976 concentration for 4 cell 
cycles (72 hours) at 37°C. Untreated K-562 cells were used as the control. By the end of 
the incubation, 2 x 10^ cells were harvested and assayed for their caspase activities. The 
activities of caspases 3，8，9 and 2 were assessed by adding the cell lysates to the 
corresponding wells in the BD A p o A l e r t ™ Caspase Assay Plates as described in 
Materials and Methods 2.4.3. 
The percentage change of the caspase activites of the untreated and LC976 
treated cells were compared using the computer software Prism®. The significance of 
the change was determined with t-test. (Figure 3.21) 
It was observed that LC976 induced a significant increase in caspase 8，9 and 
2 activities (P < 0.05) compared with the untreated control. Though the increase of 
caspase 3 activity was not statistically significant shown by the P value obtained by 
t-test, a general higher caspase activity was seen in the LC976 treated group. 
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Figure 3.21 LC976 induced a change of caspases activities in K-562. 
K-562 cells were incubated at 260|ig/mL LC976 concentration for 72 hours at 37°C. 
Untreated K-562 cells were used as the control 2 x 10^  cells were lysed and added to 
the corresponding wells in the BD ApoAlert™ Caspase Assay Plate as described in 
Materials and Methods 2.4.3. The OD460 reading of the LC976 treated cells was 
normalized with the untreated control group as the percentage change of caspase 
activites. The assays were performed in triplicate. The significance of the change in 
caspase activities was determined with t-test using the computer software Prism®. 
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3.4 Effect on Normal Human Lymphocytes 
3.4.1 MTT Cell Viability Assay 
MTT assay was used to determine the cytotoxic effect of LC976 on the 
normal human lymphocytes. 8x10"^ cells were seeded per well of the 96-well culture 
plates and treated with different concentrations of LC976 as described in Methods and 
Materials 2.5.2. The culture plate was incubated for 48 hours at 2>TC. 
The percentage of survival of the cells was plotted against the log of 
concentration of LC976 using the computer software Prism®, with non-linear regression. 
EC50 of LC976 on the normal human lymphocytes was also found from the curve. 
(Figures.22) 
The normal human lymphocytes survived the low LC976 concentrations, 
while more cells were killed at progressively higher concentrations of LC976. The 
EC50 of LC976 on the normal human lymphocytes was found to be 79.27|ag/mL. 
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LC976 Effect on Normal Human 
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Figure 3.22 Percentage of survival of normal human lymphocyte with LC976 
treatment. 8 x 10^ normal human lymphocytes per well in 96-well culture plate were 
incubated with different concentrations of LC976 at 37°C, 5% CO2 level and 95% 
humidity for 48 hours. The MTT assay was then performed as described in Materials 
and Methods 2.5.2. Untreated normal human lymphocytes seeded in the same plate 
were used as the control. The O D 5 7 0 reading of the treated cells was normalized as the 
percentage of survival, and plotted against the log of LC976 concentration with the 
computer software Prism®. The assay was performed in triplicate. 
77 
a Chapter 3 Results 
3.4.2 PI Staining 
Normal human lymphocytes were incubated with different LC976 
concentrations (260|ig/mL, 130|ig/mL, 65|ag/mL, 33|ag/mL and 17|ag/mL) for 24 hours. 
The untreated normal human lymphocytes were used as the control. After incubation, 
the cells were fixed and stained with PI as described in Materials and Methods 2.5.3. 
The slides were then mounted onto the slides with nail polish and cellotape. The slides 
were observed under the confocal microscope with laser emission at 488nm. Pictures of 
both the fluorescence field and the bright field of the cells were taken. (Figure 3.23a to 
1) 
Apoptotic cells with condensed and segregated nucleus were observed in 
normal human lymphocytes incubated with high LC976 concentrations, 260|ag/mL. At 
lower LC976 concentrations, apoptotic cells were rarely found. But the lymphocytes 
showed different morphologies at lower LC976 concentrations. The lymphocytes were 
found 'carrying' a small empty sac on them. At 17|ig/mL, most cells showed this 
morphology. 
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Figure 3.23a-l PI staining to show apoptosis and morphology of normal human 
lymphocytes induced by LC976. 
Normal human lymphocytes were incubated with different concentrations of LC976 for 
48 hours. They were then fixed and stained with PI according to Materials and Methods 
2.5.3. The stained cells were observed under the confocal microscope with laser 
excitation at 488nm. Both the fluorescence field and the bright field are shown, a and b: 
normal human lymphocytes treated with 260|ig/mL LC976, fluorescence and bright 
fields respectively, c and d: normal human lymphocytes treated with 130|j,g/mL LC976, 
fluorescence and bright fields respectively, e and f: normal human lymphocytes treated 
with 65|ag/mL LC976, fluorescence and bright field respectively, g and h: normal 
human lymphocytes treated with 33|ig/mL LC976, fluorescence and bright fields 
respectively, i and j: normal human lymphocytes treated with 17|ag/mL LC976, 
fluorescence and bright fields respectively, k and 1: Untreated K562 cells used as the 
control, fluorescence and bright fields respectively. 
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3.4.3 Annexin V-FITC FACS Analysis 
Normal human lymphocytes were incubated at 260|j,g/mL LC976 
concentration for 24 hours at 37�C. Untreated normal human lymphocytes were used as 
the control. By the end of the incubation period, 1.5 x 10^  cells of each sample were 
stained with Annexin V-FITC and PI for FACS analysis as mentioned in Materials and 
Methods 2.5.4. The data of FACS were represented in the dot-plot format by the 
computer software Expo32 ADC. (Figure 3.24a-b) 
LC976 was able to induce apoptosis in normal human lymphocytes shortly 
after it was added to the cells. 
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Figure 3.24a-b Annexin V-FITC FACS Dot-plot to show apoptosis of 
normal human lymphocytes induced by LC976. Normal human lymphocytes were 
treated with 260)^g/mL LC976 for 24 hours. 1.5 x 10^  cells were stained with Annexin 
V-FITC and PI as described in Materials and Methods 2.5.4. FACS analysis was then 
performed and the data were analyzed by the computer software Expo32 ADC. The 
percentage of cells gated into each region of the dot-plot was shown in the table, a: 
Untreated normal human lymphocytes were used as the control, b: Normal human 
lymphocytes treated for 24 hours. 
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Table 3.3 Comparison of the percentage of cells of different apoptotic stages 
upon 24-hour LC976 treatment between K-562 cells and normal human 
lymphocytes 
Percentage Gated (%) 
Region Untreated LC976 Percentage Untreated LC976 Percentage 
K-562 Treated difference NHL* Treated difference 
K562 {%f NHL* (%)' 
'S\ ^ ^ ^ L46 3.58 2.12 
^ 2J5 17.78 15.03 16.86 SlTl 35.85 
^ 83.26 ^ -76.86 71.86 11.64 -60.22 
^ 13.57 61.63 ^ 32.08 22.26 
T o t a l 1 0 0 . 0 0 100.00 “ 100.00 100.00 --
_ i 
* NHL = Normal human lymphocytes 
# Percentage difference = Percentage gated in LC976 treated group — percentage gated in 
untreated group 
After the Annexin V-FITC FACS analysis of K-562 and normal human lymphocytes, 
the percentage difference of the cells of different apoptotic stages (gated into different 
regions) were compared to study the effect of LC976 on the 2 cell types. The percentage 
difference was calculated by subtracting the percentage gated of the untreated cells of 1 
region from the percentage gated of the LC976 treated cells of that region. 
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Chapter 4 Discussion 
4.1 Extraction of LC976 
My lab-mate Xing H. T. preliminarily found that a lead compound in 
Trichosanthes sp. induces fetal hemoglobin production as well as an anti-proliferation 
effect in K-562 cell line. So we want to investigate these findings in detail. 
The first step is to extract the lead compound from Trichosanthes sp.. Since 
the chemical structure of the lead compound is not yet defined, we could only design 
the extraction protocol according to our limited knowledge to its chemical properties. 
This compound is well soluble in organic solvents like alcohol, and only 
partially soluble in water. For the sake of safety and easy availability, we used EtOH to 
extract the compound. But since a lot of substances in Trichosanthes sp., which is a 
plant part, also dissolved in EtOH, we performed a series of purification protocol to 
remove the unwanted substances. 
If these substances were not removed, it could greatly affect our experiment 
efficiency and accuracy: The plant pigments, like chlorophylls and xanthophylls, could 
greatly affect OD measurement in the MTT assay and the BrdU cell proliferation 
ELISA. Also, any effect on the cell lines would be due to multiple factors, which we 
cannot attribute the effects to any compound specifically. In the course of the 
development of a drug, it is essential to know which compound gives our desired 
effects. 
Since the lead compound would be precipitated below 15% EtOH, we tried to 
precipitate the impurities with 35%，25% and 15% EtOH. Through these precipitations, 
a large portion of the non-polar plant pigment were removed, and the viscosity of the 
drug extract drops. 
Then reversed-phase column extraction was performed to remove the 
remaining impurities. The cartridge contains beads coated with 18-C carbon chains. 
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These carbon chains bind compounds what have similar polarity. Since the lead 
compound dissolved in non-polar solvents, the carbon chains in the cartridge retained it. 
Other substances that were not bound by the beads were removed and washed away. We 
used 40% MeOH to wash away more polar substances that were also retained in the 
cartridge. Hence, 60% MeOH was used to elute the lead compound. It was our lab 
mates that collected different portions of the effluents for cell assay to confirm that our 
desired lead compound was eluted with 60% MeOH. 
After the reversed phase column extraction, the volume of the extract was too 
large that would consume much time to be lyophilized. So the volume of the extract was 
reduced by rotary evaporation. The lyophilized product was weighed and dissolved in 
95% EtOH, hence filtered for use in the cell cultures. 
4.2 LC976 Inhibited Proliferation of Human Cell Lines 
4.2.1 MTT Assay 
In this MTT assay, it was used to evaluate the anti-proliferation effect of 
LC976 on various human cell lines. The yellow MTT tetrazolium was reduced by the 
dehydrogenase in mitochondria, and formed the intracellular purple formazan. 
Therefore DMSO was used to lyse the cells, release the purple formazan, as well as to 
solubilize it. With the three assumptions: All cells used in the assay carry the same 
number of mitochondria; the activity of all live mitochondria is the same; mitochondrial 
dehydrogenase activity stop as soon as the cell die, the amount of purple formazan 
formed reflect the number of viable cells present. (Liu et al.，1997; Mosmann, 1983; 
Zhang et al., 2003) 
In this assay, as the cells treated with LC976 were cultured for 4 cell cycles 
(ranged from 72 to 120 hours), the number of viable cells present after the incubation 
actually reflects the proliferation of the cells, with the premise that the human cancer 
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cells in the normal condition replicate continuously. 
In the 9 human cell lines we evaluated, 8 are cancer cell lines, K-562, HL-60, 
5637, Hela, A375, MG-63, MCF7 and PC-3, and 1 is normal cell line BUD-8. But as 
BUD-8 cells are s skin fibroblasts, they are capable of replication for several cycles. So 
we evaluated BUD-8 with the same technique as the cancer cell lines. 
Among the human cell lines evaluated, all of their proliferation was stopped 
by LC976, but the dose of LC976 required is different for every cell line. The EC50 
value was used as the index to reflect cells' response towards LC976. EC50 refers to the 
LC976 concentration that the proliferation of the cells was reduced by 50%. We could 
generally divide the cell lines according to the anti-proliferation response towards 
LC976: High responder, which the cell proliferation was stopped by a low dose of 
LC976; Medium responder, which the cell proliferation was stopped by a medium dose 
of LC976; and low responder, which the cell proliferation was stopped only when a high 
dose of LC976 was used. This assessment is only arbitrary. 
The high responders include BUD-8 (EC50 = 2.68|ag/mL), A375 (EC50 = 
2.579|ig/mL), PC-3 (EC50 = 2.472^g/mL), 5637 (EC50 = 2.065|^g/mL) and MG-63 
(EC50 = 0.947|ag/mL). The medium responders include HL-60 (EC50 二 7.169fig/mL), 
Hela (EC50 = 4.245|ig/mL). The low responders include MCF-7 (EC50 = 7.150|ag/mL) 
and K-562 (EC50 = 30.970|ag/mL). 
Since cells from different origins have different cellular machineries, as well 
as cancer cells always show different and abnormal cell physiologies, the cell lines we 
accessed showed very different response towards LC976. 
It is not surprising to find the normal cell line BUD-8 being one of the high 
responders. Though we hoped that LC976 would only target cancer cell lines, many 
anti-cancer drugs do attack normal replicating cells as well. This may be one of the 
clues to our future study to the mechanism of how LC976 affects the cells. 
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However, in the course of this experiment, we found a weakness of this MTT 
assay. When evaluating K-562 cells, it was found that the cells differentiated in some of 
the LC976 concentrations. The cells became very big, which were 3 to 4 times as big as 
the ordinary K-562 cells. These cells produced a lot of purple formazan, which the 
amount was also 3 to 4 times more than the ordinary cells. We still do not know whether 
the number of mitochondria in these cells was increased, or the mitochondrial activity 
of the individual mitochondrion was increased. In this situation, the amount of purple 
formazan formed did not reflect the viable cell number. With the assumptions to validate 
the results of the MTT assay, which is described above, being violated, we need other 
assays to determine the anti-proliferation effect of LC976 more accurately. We chose the 
BrdU cell proliferation ELISA and would be described in the next section. 
Because Percentage of Proliferation was calculated by: 
O D ^ of LC976 treated group x 100% 
OD570 of no drug control group 
When the Percentage of Proliferation became 0 at higher LC976 concentrations, no 
tetrazolium MTT was converted to the purple formazan. This means that at higher 
LC976 concentrations, not only the cell proliferation was halted, the cells were also 
non-viable. So, LC976 was also cytotoxic to the cells. 
With the results of MTT assay, it showed LC976 had anti-proliferation and 
cytotoxic effect on various human cancer cell lines. But it is critical to know if LC976 
induced cell death through necrosis and apoptosis. This would be described in the later 
part (4.3). 
4.2.2 BrdU Cell Proliferation ELISA 
This assay was performed to evaluate the anti-proliferation effect on various 
human cell lines by LC976. 
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BrdU Cell Proliferation ELISA was performed due to the weakness of MTT 
assay mentioned above in 4.2.1. The problem of the colored product formed not 
representing the actual cell number would not be encountered in this ELISA assay. 
BrdU is a DNA base analog that would insert into the genome when the cell 
replicates. After incorporation of BrdU into the cell genome, the cells are lysed and the 
incorporated BrdU is detected with anti-BrdU antibody that is conjugated with a 
peroxidase. The peroxidase then converts the substrate to a blue product, and the 
amount of blue product formed represents the level of proliferation. The higher the 
proliferation rate, the more BrdU is incorporated, and hence more blue product formed. 
(Gratzner, 1982; Porstmann et a l , 1985; Vanderlaan and Thomas, 1985) 
In this assay, since every cell only uptake BrdU when it divides, and every 
cell contains and produces the same amount of DNA in 1 division, this assay avoids the 
problem encountered in the MTT assay. 
In the 8 human cell lines evaluated, 7 are cancer cell lines, K-562, 5637, Hela, 
MG-63, MCF7, PC-3 and HepG2，and 1 is normal skin fibroblast BUD-8. 
Similar to the results of the MTT assay, different cell lines responded 
differently towards LC976. Their EC50 values were also compared. The cell lines could 
also be divided into 3 groups, high, medium and low responders. Though the response 
ranking of cell lines was different (Table 3.1.2.1 and Table 3.2.2.1) and the cell lines 
assayed were different, the general grouping with cell lines evaluated in both assays 
were similar. 
From the BrdU cell proliferation assay, the high responders were 5637 (EC50 
=1.789}ig/mL) and PC-3 (EC50 = 1.419|ag/mL); the medium responders were Hela 
(EC50 = 4.201 lag/mL), BUD-8 (EC50 = 3.355) and MG-63 (EC50 = 3.29|ag/mL), and 
the low responders were MCF-7 (EC50 = 138.75|ig/mL), HepG2 (EC50 = 128.5|ag/mL) 
and K-562 (EC50 = 65.07|ig/mL) 
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The BrdU cell proliferation assay also showed that LC976 had 
anti-proliferation effects on various cancer cell lines as well as on normal skin fibroblast. 
It was worthwhile to proceed to the subsequent analysis to determine whether LC976 
was a good anti-cancer drug candidate. 
Due to the limitation of time and resources, only K-562 was chosen for the 
subsequent analysis on apoptosis. It was chosen because other members of our team 
were working on the fetal hemoglobin induction in K-562 by LC976. The information 
of anti-cancer ability of LC976 would help give the broader picture of the effect of 
LC976 on K-562. It is observed that commercially available drug, like hydroxyurea, to 
have dual effects to induce fetal hemoglobin in erythroid cells and to kill leukemia cells. 
(Voskaridou et a l , 2002) 
As the future work, one cell line from each responder group would be further 
evaluated. If time and resource allows, all cell lines assayed should be subjected to 
further studies on apoptosis to understand more how LC976 work on different cell lines. 
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4.3 LC976 Induced Apoptosis in K-562 Cells 
4.3.1 PI Staining 
PI particles bind to DNA by intercalating between the bases. They are 
excluded by the cell membranes of the viable cells. So, we had to partially disrupt the 
cell membrane by PFA to allow PI to enter to cells. When PI binds to the DNA, it 
absorbs energy at 540nm and emits fluorescence at 610nm, so that the stained cells 
appears red in color. 
In apoptosis, various executioner caspases are activated to cleave the cellular 
substrates. When the nuclear lamins are cleaved, the chromosomes condense and the 
nuclear shrinks.(HeiT and Debatin, 2001; Igney and Krammer, 2002) These condensed 
chromosomes can be visualized by PI staining. (Chakrabarty et al., 2002; Tas and 
Westemeng, 1981) 
In our experiment, it was observed that apoptotic cells (cells with condensed 
chromosomes) were present at high LC976 concentrations. The higher the LC976 
concentrations, the higher proportion of apoptotic cells was found. The actual 
proportion of the apoptotic cells was not determined, since manual determination and 
cell counting were not objective. The proportion of apoptotic cells was determined by 
Annexin V-FITC and PI staining for FACS analysis to be described later. 
The K-562 cells were incubated with LC976 for different time periods, 36 
hours and 54 hours. The time difference did not affect much to the apoptotic induction 
effect to K-562 at high LC976 concentrations. Similar proportions of apoptotic cells 
were observed. With 54 hours LC976 treatment, apoptotic cells were observed at 
260)ig/mL, 130fig/mL and 65|^g/mL. With 36 hours drug treatment, apoptotic cells were 
observed at 260|ag/mL and 130|ag/mL. However, the time difference gave different 
patterns of the cell morphology differentiation. In both time periods, K-562 cells with 
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‘dendrite-like’ protrusions or filaments were found at low LC976 concentration, 
33|j,g/mL. Whereas at longer time of LC976 treatment, 54 hours, tapered end cells and 
many small vesicles were observed at 65)a,g/mL of LC976. It was reported that K-562 
could form exosomes when induced by different chemicals. (Ikeda et al., 2005; Savina 
et al., 2002) However, the exosomes are usually small membrane vesicles of 60-80nm 
diameters. In the vesicles we found, they were of 15-20|im diameters, what were much 
larger than normal exosomes. So the identity of these vesicles is still unknown. In 
untreated cells, they remained spherical, and no condensed chromosome was found. 
The K-562 dendritic-like morphology is a very interesting discovery. It was 
reported that K-562 could be induced to differentiate to DC by phorbol ester PMA or 
TNF-a. These differentiated K-562 cells could activate T cells to comparable levels as 
the normal DC (Lindner et al , 2003). DC is currently under hot investigation for the 
development of cancer vaccines as they are effective antigen-presenting cells to 
facilitate T cell response. Conventional experiments needed the loading of the limited 
number of cancer antigens into the natural DC. However in more recent findings, 
leukemic cells could be transformed into DC so that they contained all cancer antigens 
present in the leukemic cells (Banchereau and Palucka, 2005; Mohty et al., 2002). It 
was hope that this kind of leukemic-derived DC could shed light to better leukemia 
vaccines. 
Therefore the LC976 induction of differentiation of K-562 to dendritic-like 
morphology is now under further investigation, which includes the studies on its 
morphology differentiation, gene expression, T cell response, etc. Preliminary results of 
the study of cytoplasmic extension development induction by LC976 on K-562 cells are 
shown in Figure 4.1a-d. K-562 cells were incubated at 65|ag/mL, 33|ig/mL and 
17}ig/mL LC976 for 48 hours. Differentiated K-562 with the cytoplasmic extension 
were observed in all these 3 LC976 concentrations, which 33|ig/mL and 17|ig/mL 
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LC976 seemed to be more effective for inducing the development of the cytoplasmic 
extensions. 
Further study would include the detection of dendrite cell markers, e.g. CD83 
and class II MHC molecules, by RT-PCR and monoclonal antibodies analyzed with 
flow-cytometry to detect the transcription and expression of those markers. If we get 
positive results, the differentiated K-562 cells would be subject to functional assay to 
test for their ability to induce T-cell proliferation, which is the characteristic property of 
DCs. 
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i i 
Figure 4.1a-d Bright field microscopic field to show the development of 
cytoplasmic extensions of K-562 cells induced by different concentrations of 
K-562 cells were incubated with different concentrations of LC976 for 48 hours (3 cell 
cycles). They were then photographed under the confocal microscope at bright field, a: 
K562 cells treated with 65|ag/mL LC976. b: K562 cells treated with 33|ig/mL LC976. c: 
K562 cells treated with 16^g/mL LC976. d: Untreated K-562 cells used as the control. 
94 
Chapter 4 Discussion 
4.3.2 Annexin V-FITC FACS Analysis 
In early apoptosis, an enzyme phospholipid phosphatidylserine (PS) is 
translocated from the inner surface of the cell membrane to the external surface. 
Annexin V is a protein that binds specifically to PS. So the Fluorescein Isothiocyanate 
(FITC) conjugated Annexin V is allowed to stain the early apoptotic cells and to be 
analyzed by flow cytometry (van Engeland et al., 1996; Vermes et al., 1995). 
However, since PS is also externalized when the cell is ruptured through 
necrosis, the vital dye PI would be needed to differentiate the cell between apoptosis 
and necrosis. Since PI is normally blocked by the cell membrane, it could only stain the 
DNA when the cell is ruptured. Therefore in early apoptosis, the cells are only stained 
with Annexin V-FITC, since PI is excluded. In late apoptosis, the cells are stained with 
both Annexin V-FITC and PI, as the cells are heavily ruptured. But at this stage, we 
cannot tell whether the cells' death is due to apoptosis or necrosis with Annexin 
V-FITC and PI stainings, since in both cases the cells are totally ruptured so that both its 
DNA and PS could be stained. 
Upon FACS analysis, the results were presented as the dot-plot. There are 4 
grids in the dot-plot. Dots in SI represent cells heavily with PI (cell ruptures). Dots in 
S2 represent cells heavily stained with Annexin V-FITC and PI (necrotic or late 
apoptotic cells). Dots in S3 represent cells not stained or only slightly stained with 
Annexin V-FITC and PI (normal cells). Whereas dots in S4 represent cells heavily 
stained with Annexin V-FITC (early apoptotic cells). 
In our experiment, it was found that LC976 induced apoptosis in K-562 in a 
time-dependent manner. The K-562 cells were treated with 260}ag/mL LC976 for 4 time 
periods, 5 minutes, 4 hours, 16 hours and 24 hours. 
We could observe that untreated cells mostly resided in S3 (83.26%). Then the 
cloud of dots generally moved rightwards and slightly upwards with increasing 
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incubation times. After 5 minutes LC976 incubation, cells were generally normal, 
mostly resided in S3 (86.69%) as in the untreated control. After 4 hours of LC976 
incubation, most cells moved rightwards to S4 (73.45%) and also more cells entered S2 
(3.12%). This means that most cells were in their early apoptosis which the cells were 
still intact (S3)，and few of them are ruptured (S2). After 16 hours of LC976 incubation, 
even more cells entered S4 (from 73.45% to 80.14%) and S2 (from 3.12% to 8.36%). 
After 24 hours of LC976 incubation, percentage of cells in S4 decreased (from 80.14% 
to 75.20%)while the percentage of cells in S2 increased further (from 8.36%to 17.78%). 
This means upon LC976 treatment, most cells underwent apoptosis and more and more 
cells were ruptured as the drug treatment time increased. Since the cells did not migrate 
from S3 to S2 directly, it was deduced that the increased number of ruptured cells (S2) 
was due to apoptosis, with the migration pathway from S3 to S4 to S2. 
From these results, it was observed that LC976 induced apoptosis in K-562 
cells but not necrosis. 
4.3.3 Caspase Activation 
Generally there are 2 pathways for apoptosis, the death-receptor pathway and 
the mitochondrial pathway. Caspases are enzymes that mediate apoptosis. Different 
caspases are involved in the pathways, and they form a complicated network which they 
affect each other, to cleave different proteins and result in apoptosis. 
Since LC976 in a newly found lead compound that induce apoptosis on 
various human cell lines. There was little known about the actual mechanism on how it 
was done. So we carried out this experiment to access which caspases were activated in 
the pathway of LC976. 
In this assay, caspase 3，8，9 and 2's activity was evaluated. Each of the 
caspase has specific peptide substrates. So in the commercial caspase assay plate, the 
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specific peptides conjugated with the fluorogenic dye 7-amino-4-methyl coumarin 
(AMC) are coated different wells. AMC would be cleaved off if the added cell lysate 
contains the corresponding caspase. The cleaved off AMC is green in color which has 
an emission maximum of 460rmi. It could be differentiated with the peptide-bound 
AMC which emission maximum is 380nm. 
From the results, we found that caspases 8，9 and 2 activity was increased 
upon treatment with 260|^g/mL LC976. The t-test gave their P values smaller than 0.05 
to show that the percentage of increase was of significance. Though caspase 3's activity 
increase gave a P value larger than 0.05, but from the data show, it was likely that its 
activity was also induced by LC976. LC976 induction of caspase 3 activity in K-562 
would be accessed again to confirm its effect. 
From the results showing all caspase 3, 8, 9 and 2 being activated, we could 
deduce the picture of apoptosis induced by LC976 on K-562. Both apoptotic pathways 
were activated by LC976: in the death receptor pathway, caspase 8 was activated at the 
death-inducing signaling complex (DISC). Then caspase 8 cleaved the BID molecule 
and this cleaved BID was translocated to the mitochondria to activate the mitochondrial 
pathway. Hence, cytochrome c was released by the mitochondria into the cytosol. Here 
it formed a complex with the apoptotic protease activating factor-1 (APAFl), ATP and 
procaspase 9. Then caspase 9 was activated in this apoptosome formed. 
Caspases 8 and 9，which were among the initiator caspases, activated the 
downstream executioner caspases, including caspase 3. These executioner caspases then 
cleave various cellular death substrates, like nuclear lamins and other enzymes, which 
resulted in various apoptotic features (Igney and Krammer, 2002; Wang et al , 2005b). 
Caspase 2，s function is still unclear. It was reported to have both the initiator 
and executioner roles in apoptosis. But its function in these roles could be actually 
replaced by other caspases. (Troy and Shelanski, 2003) Most recently, it was reported 
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that caspase 2 was a regulator upstream to the mitochondrial pathway. It helped regulate 
the permeability of the mitochondria to control to release of pro-apoptotic factors. (Guo 
et al., 2002; Lassus et al., 2002; Paroni et al., 2002) 
To sum up, LC976 seemed to induce all apoptotic pathways to cause the death 
of the cells. This ability rendered its high efficiency to kill the 'nasty' cancer cells, with 
certain apoptotic pathway hampered of caspases absent, like MCF-7 lacking caspase 3. 
4.4 Effect on Normal Human Lymphocytes 
4.4.1 MTT Cell Viability Assay 
. To know whether LC976 was a good candidate of anti-cancer drug, besides 
LC976’s anti-cancer and anti-proliferation effect on the human cancer cell lines, we also 
need to evaluate its effects on normal human cells. The ideal anti-caner drug candidate 
would be those only targeting cancer cells with minimal or no effect to normal cells. 
And the fact that many of the available anti-cancer drugs have adverse effects to the 
general health of the patients is one of the reasons that scientists are still working for 
better drugs. 
As the isolation procedure of human lymphocytes from the peripheral blood 
was easy and reliable with Ficoll Plaque Plus reagent, normal human lymphocytes were 
chosen in the assays for LC976 treatments on normal human cells. 
In this experiment, MTT assay was employed to evaluate the cytotoxic effect 
of LC976 on normal human lymphocytes. The principles behind the MTT assay were 
mentioned before in 4.2.1. In this experiment, since the normal human lymphocytes did 
not replicate, the MTT assay was just to evaluate the viability of the cells upon LC976 
treatment. And also due to the inability of the lymphocytes to divide, the cells had 
limited life span of about a week in vitro. So the lymphocytes were only incubated with 
LC976 for 48 hours. 
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It was observed that the normal human lymphocytes were killed at high 
concentrations of LC976, with its EC50 equals to 79.27|ag/mL. This value is higher than 
most of the EC50 values for LC976 to inhibit the proliferation of the human cell lines 
evaluated by MTT assay and BrdU cell proliferation assay in 4.2.1 and 4.2.2. In these 2 
assay, only MCF-7 (in both MTT and BrdU assays) and HepG2 (in BrdU assay) 
required LC976 concentration higher than 79.27|ig/mL to reduce their proliferation by 
half. 
Therefore from the results of this experiment, it was showed that LC976 had 
lower toxicity in normal human lymphocytes than in most of the human cancer cell 
lines. LC976 could kill most cancer cells before normal lymphocytes were killed or 
harmed. 
4.4.2 PI Staining 
Normal human lymphocytes incubated with different LC976 concentrations 
were stained with PI to show if LC976 induced apoptosis in the lymphocytes. The ideal 
anti-caner drug candidate would be those only targeting cancer cells with minimal or no 
effect to normal cells. The normal lymphocytes were only treated for 48 hours. We 
avoided longer treatment time, as natural apoptosis would occur in around 5 days after 
the cells were isolated from the human for they had limited life span. 
From the experiments, cells with condensed chromosomes were only found at 
high LC976 concentration, 260|^g/mL. When compared to the PI staining results of 
K-562, which apoptotic cells were observed at 260|^g/mL, ISO^ig/mL and 65|ig/mL 
(only observed in 54 hours LC976 treatment), LC976 was less efficient to induce 
apoptosis in normal lymphocytes than in K-562 cells. 
At low LC976 concentrations, 33^g/mL and 17|ig/mL, small empty vesicles 
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were found annexed to the lymphocytes. Whereas the untreated cells remained spherical 
without condensed chromosomes. 
From the PI staining results, LC976 had lower apoptosis-inducing effect on 
normal human lymphocytes when compared to the PI staining results of K-562 cells. 
However the results was not totally reliable as only a few cells were shot in each picture. 
For higher accuracy, Annexin V-FITC FACS analysis had to be carried out. 
4.4.3 Annexin V-FITC FACS Analysis 
Annexin V-FITC and PI staining were carried out to study if LC976 induced 
apoptosis on normal human lymphocytes. The detailed principle of the experiment was 
described in 4.3.2. 
After 260|ag/mL LC976 treatment for 24 hours, the normal human 
lymphocytes were subjected to Annexin V-FITC and PI staining and analyzed with flow 
cytometry. 
Upon FACS analysis，the results were presented as the dot-plot. There are 4 
grids in the dot-plot. Dots in SI represent cells heavily with PI (cell ruptures). Dots in 
S2 represent cells heavily stained with Annexin V-FITC and PI (necrotic or late 
apoptotic cells). Dots in S3 represent cells not stained or only slightly stained with 
Annexin V-FITC and PI (intact cells). Whereas dots in S4 represent cells heavily 
stained with Annexin V-FITC (early apoptotic cells) 
It was observed that the untreated cells mainly resided in S3 (71.86%). Since 
these cells had limited life span, at the time when this assay was carried out, the cells 
had already isolated from the human body for 3 days. Therefore relative large 
percentage (9.82% in S4) of the cells was already in apoptotic stage and ruptured 
(16.86% in S2) when compared to the K-562 cells described in 4.3.2. 
Upon LC976 treatment, we observed a shift of the cells from S3 to S4 and S2. 
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The percentage of cells in S4 increased from 9.82% to 32.08%, which means that a 
higher proportion of cells were apoptotic after LC976 treatment. And the percentage of 
cells in S2 increased from 16.86% to 52.71%. This meant that more cells were apoptotic 
and even heavily ruptured when treated with 976. 
The results of the normal human lymphocytes were compared to K-562. Due 
to the anti-proliferation effect of LC976 on K-562, the addition of 260|ig/mL LC976 to 
K-562 stopped its proliferation. 
The comparison showed that LC976 effectively induced apoptosis in normal 
human lymphocytes, and the effectiveness is even higher than to induce apoptosis in 
K-562 (4.3.2). K-562 treated 260|ig/mL LC976 for 24 hours gave a shift of early 
apoptotic cells in S4 from 13.57 % to 75.20%, and ruptured cells in S2 from 2.75% to 
17.78%. This observation was contradictory to the MTT assay and the PI staining 
results, which they showed that LC976 induced apoptosis in K-562 more effectively 
than in the normal human lymphocytes. 
However, it is interesting to note the change in cell proportion in S3, the 
normal non-apoptotic cells. In K-562, the non-apoptotic cells in S3 decreased by 
76.86% upon LC976 treatment. Whereas the non-apoptotic cells in S3 of normal human 
lymphocytes decreased by 60.22%. It seemed that smaller percentage of cells was 
induced to be apoptotic by LC976 in the normal human lymphocytes. 
Also, from the dot-plot pattern of both cells types, it was shown that the 
normal human lymphocytes were more dispersed in the dot-plot, whereas K-562 cells 
tended to be located closely. This shows that normal human lymphocytes gave more 
diverse response towards the effect of LC976; it could be due to the 'contamination' by 
other blood cells in the lymphocyte isolation procedures. Whereas K-562 cells 
responded similarly towards LC976. 
Though this experiment seemed to give contradictory results, we have to note 
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that the normal human lymphocytes were treated with 260|ig/mL of LC976, whereas the 
EC50 for LC976 to inhibit proliferation of K-562 is just 65|ag/mL. So we still do not 
know whether the normal cells are still apoptotic if they are treated with lower LC976 
concentration like 65|ag/niL. Therefore we need to further study the apoptotic effect of 
LC976 on normal human lymphocytes at different LC976 concentrations and treatment 
times. 
Since this experiment gave different views to interpret the results, and we still 
have many unsure factors in the experiment, we could only draw the conclusion that 
LC976 induced apoptosis in normal human lymphocytes. However, we are still unsure 
about its preferential action between cancer cells and normal cells, and also whether it is 
a good anti-cancer drug candidate. 
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4.5 Conclusion 
LC976 was found effective to inhibit proliferation and cytotoxic to 9 human 
cell lines, K-562, HL-60，5637，Hela, A375, MG-63, MCF7, PC-3, HepG2 and BUDS 
by MTT assay and BrdU cell proliferation ELISA. In general, K-562, MCF-7 were the 
most tolerant to LC976, where PC-3, 5637 and MG-63 were the most sensitive to 
LC976. 
Further studies showed that LC976 induced apoptosis in K-562. When K-562 
cells were treated with LC976，condensed chromosomes and fragmented nucleus were 
stained with PI, and the PS translocated to the external of the membrane was stained 
with Annexin V-FITC and PI and was detected by flow cytometry. Also, caspases 8，9，2 
and possibility caspase 3 were found activated for apoptosis. This showed that both the 
death-receptor mediated pathway and the mitochondria mediated pathway were initiated 
by LC976 in K-562 cells. 
In the PI staining of LC976 treated K-562 cells, dendritic-like structure was 
observed. This observation gave new insights for the possibility to the use of LC976 to 
aid the development of cancer vaccine. But this requires further investigations. 
However, LC976 was found also being cytotoxic to normal human 
lymphocytes in the MTT assay. And it was observed that LC976 induced apoptosis in 
these normal lymphocytes. When the LC976 treated lymphocytes were stained with PI, 
condensed chromosome and fragmented nucleus were observed. When they are stained 
with Annexin V-FITC and PI and analyzed by flow cytometry, cells were found heavily 
apoptotic. 
This shows that LC976 was cytotoxic to both cancer cells and normal cells. 
While it needs further evaluation on its actual toxicity to animals to determine if LC976 
is too toxic to be an anti-cancer drug. However, its ability to induce K-562 into 
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